DAX+0,19 % EUR/USD+0,02 % Gold+0,05 % Öl (Brent)0,00 %

ChromaDex (smallcap) - A Philipp Frost (Billionair) Investment - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Dr. Phillip Frost is biggest investor in ChromaDex

When billionaire uber investors such as Warren Buffett of Bershire Hathaway (NYSE: BRK-A) and David Einhorn of Greenlight Capital (NASDAQL GLRE) take a position in a company as Dr. Phillip Frost has in ChromaDex Corporation (OTC: CDXC), the financial world takes notice. It is particularly of note when an investor the magnitude of Dr. Phillip Frost invests in a small cap like ChromaDex Corporation. Even more significant is that he is the largest shareholder at around 20%.

Dr. Phillip Frost, a medical doctor, now owns a sizable chunk of ChromaDex Corporation. ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic, and pharmaceutical industries. The company recently entered into a supply and licensing agreement with Cott Corporation (NYSE: COT), the largest private label beverage maker in the world. ChromaDex (CDXC) has also entered into "a supply partnership with Organic Revolution Worldwide LLC to launch a series of gourmet snacks and grocery items under the Dodo Organics label. Organic Revolution Worldwide is the first food company to incorporate pTeroPure®into food products. The company will introduce pTeroPure® into its Dodo Organics line of nutrition bars and cookies." These and other agreements should have products with ChormaDex ingredients on the shelves of major retailers around the world.

Dr. Phillip Frost has been called an investing genius in some articles. From his Forbes profile: "Phillip Frost, M.D. Dr. Frost became the CEO and Chairman of OPKO Health, Inc. upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc. on March 27, 2007. Dr. Frost was named the Chairman of the Board of Teva Pharmaceutical Industries, Limited, or Teva, (NasdaqGS:TEVA) in March 2010 and had previously been Vice Chairman since January 2006 when Teva acquired IVAX Corporation, or IVAX. Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1986. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Dr. Frost was named Chairman of the Board of Ladenburg Thalmann Financial Services Inc. (NYSE Amex:LTS), an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006 and has been a director of Ladenburg Thalmann from 2001 until 2002 and again since 2004. Dr. Frost also serves as Chairman of the Board of Directors of PROLOR Biotech, Inc. (NYSE Amex: PBTH), a development stage biopharmaceutical company. He serves as a member of the Board of Trustees of the University of Miami and as a Trustee of each of the Scripps Research Institute, the Miami Jewish Home for the Aged, and the Mount Sinai Medical Center. Dr. Frost is also a director of Castle Brands (NYSE Amex:ROX), a developer and marketer of premium brand spirits, and Continucare Corporation (NYSE Amex:CNU), a provider of outpatient healthcare services. Dr. Frost previously served as a director for Northrop Grumman Corp., Ideation Acquisition Corp., Protalix Bio Therapeutics, Inc., and SafeStitch Medical Inc., and as Governor and Co-Vice-Chairman of the American Stock Exchange (now NYSE Amex)."

Enough said.

While Dr. Phillip Frost is not as prominent as a Warren Buffett (BRK-A) or a David Einhorn (GLRE), this presents a huge opportunity to investors. When an investment is made by a Buffett or an Einhorn, many times the stock will rise sharply. Dr. Phillip Frost, on the other hand, has been called a "hidden star" in investing. "Quiet money" is another phrase that comes to mind, in the most complimentary meaning of it.

About his investment in ChromaDex, Dr. Phillip Frost stated, "It is with enthusiasm that we make this investment in ChromaDex. The Company has a solid reputation and an experienced management team with considerable expertise in identifying and developing innovative and novel phytochemical ingredients. Moreover, we are impressed with the prospects for the Company's product and IP portfolio, including pterostilbene, a unique compound that has considerable market potential."

Dr. Phillip Frost, Cott Corporation (COT), etc... those are some pretty big names to be associated with a company the size of ChromaDex Corporation. This is very impressive, to say the least. It is also what is known as a tremendous opportunity for small cap investors. Dr. Phillip Frost, Warren Buffett, and David Einhorn are billionaire investors for a reason: they are the classic "smart money." That is not an opinion, that is just a plain and simple empirical fact. Along with being smarter (and better) investors, they have superior research resources. This results in shrewd, profitable investing. Many do well emulating their investing choices. You can read about this on their Forbes biography.

http://www.smallcapnetwork.com/Dr-Phillip-Frost-is-biggest-i…
Antwort auf Beitrag Nr.: 43.086.079 von montamero am 25.04.12 13:31:37Published: December 21, 2011 8:45:07 AM PST

Na, Danke
RedChip Promo von HEUTE: http://www.redchip.com/visibility/investor.asp?symbol=CDXC&from=reqreport

RedChip Research Issues Research Update on ChromaDex Corp.
Press Release: RedChip Companies Inc. – 1 hour 10 minutes ago


ORLANDO, Fla., April 25, 2012 (GLOBE NEWSWIRE) -- RedChip Research, a division of RedChip Companies, Inc., today announced it has issued a research update on ChromaDex Corp. (CDXC.OB - News), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries.

To receive a complimentary copy of the RedChip Research Report for CDXC, please visit: http://www.redchip.com/about/aboutmain.asp?rid=407

To learn more about Chromadex Corp., visit http://www.redchip.com/visibility/investor.asp?symbol=CDXC

About RedChip Companies, Inc.

RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Beijing, China; Paris, France; and Seoul, Korea. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.

http://finance.yahoo.com/news/redchip-research-issues-resear…
Diesen Preis sehen wir bald nicht mehr!
Konnte heute noch welche zu 0,55 abgreifen! YEAH!
Eine Werbeagentur für die BluScience Linie wurde bereits engagiert.
Dr. Frost und das Management kauften einen großen Teil ihrer Aktien um 0,75$ ein.
Die MM's versuchen den Preis zu drücken und billig zu laden....seht auch die Trades an, eine vielzahl von kauf/verkauf zu 100, 200 oder 300 Stück.
Market Maker Signals on Level ll

100 - I need shares.
200 - I need shares badly,but do not take the stock down.
300 - Take the price down so I can load shares
400 - Keep trading it sideways.
500 - Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
505 - Short on Shares
911 - Pending News
Seht euch auch Intellect Neuroscience (ILNS) mal an.
Zu diesem Investment ist zu sagen dass David Blech alias Chassman ca. 65% von ILNS hält. Näheres ist hier zu entnehmen:

http://www.wallstreet-online.de/diskussion/1173897-1-10/inte…
OPKO Health, Inc. Invests in ChromaDex® Corp.

ChromaDex Grants OPKO Marketing Rights for Latin America

MIAMI & IRVINE, Calif., Feb. 16, 2012 /PRNewswire/ -- OPKO Health, Inc. and ChromaDex Corporation (OTCBB: CDXC) announced today they have entered into a strategic alliance pursuant to which ChromaDex has licensed to OPKO all of its new product offerings and health care technologies for distribution and business development throughout all of Latin America. The initial products to be commercialized are BluScience™ (www.bluscience.com), ChromaDex's recently launched line of dietary supplements, as well as ChromaDex's proprietary pterostilbene, branded as pTeroPure® (www.pteropure.com). OPKO recently made a $1,000,000 investment in ChromaDex as a participant in a private placement of 4,993,329 shares of ChromaDex common stock.



Dr. Phillip Frost, OPKO's Chairman and Chief Executive Officer, commented, "This new agreement with ChromaDex will utilize OPKO's extensive marketing and sales experience in Latin America to commercialize ChromaDex's products and technologies throughout the region. We are enthusiastic about pTeroPure®, one of the most promising natural ingredients to be introduced in some time, as it will help with OPKO's strategy of introducing interesting new products in rapidly growing markets."

Commenting on the announcement, Jeffrey Himmel, CEO of ChromaDex stated, "Partnering with OPKO provides a unique opportunity for ChromaDex. OPKO's resources and capabilities in Latin America make it an ideal partner. We see Latin America as a bright spot with great long-term economic prospects. The alliance with OPKO is the perfect platform to exploit our new product offerings and healthcare technologies."

ChromaDex recently launched BluScience™ (www.bluscience.com), an innovative line of dietary supplements. The novel ingredient in BluScience™ is pterostilbene, branded as pTeroPure® (www.pteropure.com), named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. pTeroPure® is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and is metabolized more slowly in the body than other polyphenols (antioxidant phytochemicals that tend to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Pterostilbene has shown promise for supporting cardiovascular health, cognitive function and anti-aging*. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits.

About OPKO Health:

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
http://finance.yahoo.com/q?s=OPK&ql=0

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights pending. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

http://www.prnewswire.com/news-releases/opko-health-inc-inve…
Antwort auf Beitrag Nr.: 43.091.216 von montamero am 26.04.12 13:10:46hallo montamero

Kannst Du in kurzen Worten erklären, was die Produkte von ChromaDex ausmachen? Wäre Klasse.
Hallo Ahorne
Der hauptsächliche Wirkstoff in den Produkten ist pTeroPure (patentiert), je nach Produkt sind auch andere pflanzliche Wirkstoffe enthalten. Z.B. TrimBlu ist ein Appetithemmer, Blu2go ein Energybooster, HeartBlu regelt Cholesterin, MemoryBlu erhöht die Konzentration, das Erinnerungsvermögen etc., EternalBlu ist ein Antiaging Produkt (eher was für die Frau).
Siehe: http://www.bluscience.com/products/index#&panel1-4

Erfahrungsberichte auf gnc.com oder walgreens.com
http://www.gnc.com/product/index.jsp?productId=11916879

Habe schon einige Feedbacks gelesen, bei TrimBlu fallen wirklich die Pfunde, Heart Blu senkt lt. feedback den Cholesterin und EternalBlu bewirkt eine schönere Haut.... was die Konsumenten halt schreiben. Diese Produkte sind jedoch erst seit April auf dem Markt,.....ich glaub Blu2go den Energybooster gibt es schon seit Herbst. Im IHub hat gestern jemand geschrieben dass das Adverdisement jetzt begonnen hat, d. h. es gibt Werbung im Radio und Spots im Fernsehen...
Investment Highlights

Potential $485 million to $600 million market opportunity for the Company's pTeroPure product

Client base includes the FDA, Cargill, Nestle, Kraft, Pfizer, and the USDA

Nationwide launch of Company?s first retail product line, BluScience, in GNC stores in 3Q11

Global Industry Analysts, a market research firm, forecasts that the global nutraceutical market will reach $243 billion by 2015

Phillip Frost, a Forbes 400 billionaire and Vice Chairman of Teva Pharmaceuticals, is a key investor in the Company

Partnered with global leaders Alcone and Chandler Chicco to advance proprietary products and branded retail lines

http://www.redchip.com/visibility/investor.asp?symbol=CDXC
Was ist pterostilbene?


ChromaDex secures first patent for pterostilbene cardio benefits

By Elaine Watson, 10-Apr-2012

Related topics: Regulation, Antioxidants, carotenoids, Cardiovascular health, Cognitive and mental function

ChromaDex has secured its first patent covering the cardiovascular health benefits of pterostilbene, an antioxidant found in blueberries and grapes that the California-based firm has synthesized to produce a nature identical branded ingredient called pTeroPure.

Pterostilbene is the star ingredient in ChromaDex's BluScience line of dietary supplements

The star ingredient in ChromaDex’s new BluScience range of dietary supplements, pTeroPure is being targeted at manufacturers of supplements and food/beverages interested in cardiovascular health, cognitive function and anti-aging.

Cardiovascular health benefits

US patent #8,133,917 , issued on March 13, is the first of several patents the firm hopes to secure surrounding pterostilbene.

The patent application was initially filed in 2004 by the US Department of Agriculture, which subsequently granted an exclusive worldwide license to all rights in the patent to ChromaDex.

It covers three key claims:
A method of lowering lipid levels and to treat or reduce the risk of dyslipidemias (eg. raised LDL cholesterol, triglycerides) via a nutraceutical composition containing pterostilbene and a carrier.
A method of lowering lipid levels via a pharmaceutical composition containing pterostilbene and a carrier.
A method to treat or reduce the risk of dyslipidemias in an individual at risk of cardiovascular disease via a pharmaceutical composition containing pterostilbene and a carrier.

Superior biological activity

A potent antioxidant, pterostilbene is claimed to have superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols.

Research chemist Agnes Rimando – who is named as one of the investors on the patent – first started studying it as a graduate student at the University of Illinois in Chicago in a bid to determine if it worked in similar ways to resveratrol.

In 2003, Rimando asked Dennis Feller, former University of Mississippi professor and chair of pharmacology, and Wallace Yokoyama at USDA Western Regional Research Center in Albany, California, to collaborate on studies of pterostilbene, targeting a protein involved in fatty acid metabolism and transport called Peroxisome Proliferator-Activated Receptor Alpha Isoform (PPAR-alpha).

Results of their work were presented at the American Chemical Society meeting in 2004 and garnered widespread attention.

Commercialization

ChromaDex has since pumped large sums into commercializing pTeroPure pterostilbene, both as a branded ingredient for sale to food and supplement makers and as the core ingredient in BluScience.

Launched at GNC last fall, BlueScience is now being rolled out in Walgreens stores across the US and are also on sale at Drugstore.com.

http://www.nutraingredients-usa.com/Regulation/ChromaDex-sec…
Recent Asthma Findings Could Open a New Market for ChromaDex (CDXC)

By Ed Liston
Published: April 16, 2012 7:14:44 AM PDT


ChromaDex Corporation (OTC: CDXC), an innovative natural products company providing proprietary, science-based ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, could benefit from recent findings related to asthma treatment.

The findings, which were published in the Journal of Agricultural and Food Chemistry, showed that pterostilbene may counteract the role of environmental pollutants and prevent the development of asthma. Pterostilbene is a compound found in blueberries.

The findings related to asthma treatment are good news for CDXC, which has developed pTeroPure, a nature identical form of trans-pterostilbene.

According to the study, human cells that line the airways indicated that benzo(a)pyrene (BaP), a compound, could enhance the development of asthma. However, exposure to pterostillbene negated such effects, the study showed. This is the first time that a study has shown an interaction between BaP and the linings of the airways. It is also the first ever study to provide evidence that pterostilbene has great potential for preventing BaP-related asthma.

The study, which was performed by researchers from Kaohsiung Medical University in Taiwan, also demonstrated that pterostilbene was more effective than resveratrol in suppressing the inflammatory response in the airway linings.
The study has further validated pterostilbene and ChromaDex’s pTeroPure as a pharmaceutical. It has also added legitimacy to the clinical trials being performed to test the compound as a treatment for cholesterol and skin cancer.

Although CDXC, at this stage, does not have a pTeroPure product in the pipeline that is solely dedicated to the treatment of asthma, the findings from the study do open a potential future market for the company.


http://www.smallcapnetwork.com/Recent-Asthma-Findings-Could-…
Das Einsatzgebiet von pterostilbene ist unglaublich groß!
Ist beinahe so als erfand man da ein neues "Aspirin" :D
Das findet heute statt:

RedChip Announces Keynote Speaker for Small-Cap New York Conference
Economic Commentator Thomas Landstreet to Keynote April 26 Event
Press Release: RedChip Companies Inc. – Thu, Apr 19, 2012 10:20 AM EDT


ORLANDO, Fla., April 19, 2012 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. ("RedChip"), an international, small-cap research and financial public relations firm, today announced that economic commentator Thomas Landstreet will deliver the keynote address at the RedChip Small-Cap New York Conference, taking place Thursday, April 26, 2012 at the Harvard Club of New York City.

Mr. Landstreet founded Standard Research Corp., publisher of "Connecting the Dots," an economic/investment research service exclusively serving the institutional investment community. He also co-founded Tell-Tale Capital Corp., a Registered Investment Advisor, in 2009.

From 2006 to 2010, Mr. Landstreet produced a popular weekly economic commentary for Laffer Associates, an economic research firm founded by famed economist Dr. Arthur Laffer. From 2003 to 2006, he was Managing Director, Head of Institutional Sales, with Avondale Partners. In 2005, The Wall Street Journal recognized Avondale for producing the single best stock-picking record among all Wall Street firms. As a speaker and writer, Mr. Landstreet shares his wit and wisdom on politics, investments and economic policy at corporate and investment conferences around the country.

RedChip investor conferences are a nationally known forum for buy-side and sell-side professionals to learn about a select group of emerging small-cap companies. During the event, attendees will have the opportunity to view corporate presentations and meet one-on-one with the CEOs of 13 companies. Presenting companies represent a wide range of sectors and industries, including oil & gas, healthcare, mining and more. Presenting companies include:
Longwei Petroleum Investment Holding Ltd. (NYSE Amex:LPH)
Newtek Business Services Inc. (Nasdaq:NEWT - News)
Asure Software, Inc. (Nasdaq:ASUR - News)
ChromaDex Corp. (OTCBB:CDXC.OB - News)
Applied Nanotech Holdings, Inc. (OTCBB:APNT.OB - News)
China Bilingual Technology & Education Group Inc. (OTCBB:CBLY.OB - News)
SMTP, Inc. (OTCBB:SMTP.OB - News)

For investors who do not have the opportunity to attend the conference in person, all presentations made at the event will be webcast live and archived for 90 days at http://www.redchip.com. For more information, visit http://www.redchip.com/conference.

Preregistration is required. Seating is limited and will be reserved on a first come, first served basis. To reserve your spot, please visit http://www.redchip.com/conference or call 1-800-REDCHIP (733-2447), Ext. 127.


http://finance.yahoo.com/news/redchip-announces-keynote-spea…
Nun der richtige Link bzw. gleich das Video zu:
CDXC Presentation from the 2012 RedChip Small-Cap New York Conference on April 26, 2012 at the Harvard Club of New York

ChromaDex® Announces Financial Results for the First Quarter 2012
Press Release: ChromaDex Corporation – Thu, May 10, 2012 5:00 PM EDT


IRVINE, Calif., May 10, 2012 /PRNewswire/ -- ChromaDex Corporation (CDXC.OB) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, today announced its financial results for the first quarter of 2012.

ChromaDex announced total revenues, prepared in accordance with United States Generally Accepted Accounting Principles ("GAAP"), of approximately $1.8 million and a net loss attributable to common stockholders of $0.05 per share for the three-month period ended March 31, 2012. As of March 31, 2012, cash, cash equivalents, and marketable securities totaled over $5.8 million.

"In the first quarter we launched our BluScience™ line of dietary supplements into a major drug chain and a specialty health and nutrition chain," stated Jeffrey Himmel, CEO of ChromaDex. "In addition, we initiated distribution of our BluScience™ products to a national pharmaceutical distributor and a leading online retailer."

"During the first quarter, we began to supply our patented pTeroPure® ingredient to the equine supplement market. This is another step in achieving our goal to build ChromaDex into a leader in the natural products industry," said Frank Jaksch, Chief Scientific Officer of ChromaDex.

Additional Financial Results & Notes

ChromaDex recorded revenue of $1,785,006 during the first quarter of 2012 as compared to $2,539,245 for the same period in 2011. The net loss attributable to common stockholders for the quarter ended March 31, 2012, was $4,431,853 as compared to a net loss of $1,156,385 for the same period in 2011. The net loss in the first quarter of 2012 was largely impacted by promotions and discounts related to the launch of the Company's BluScience™ products. In addition, ChromaDex initiated a national advertising campaign through television and radio in support of the launch of its BluScience™ products, which resulted in additional marketing expenses. The non-cash, share-based compensation expense related to the stock options and other share-based compensation for the first quarter of 2012 was $65,987. The effect of this, which is a "non-GAAP measure," decreased the net loss for the first quarter of 2012 to $4,365,866.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® (www.pteropure.com) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements, now available at a major drug store chain, a national products retailer, and an online retailer. Capitalizing on the diverse potential applications of the product, ChromaDex is also investigating pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi. For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Lonza and Intellect Neurosciences Announce Intellect’s Intention to Award Production of its Antibody Drug Conjugate, CONJUMAB-A


New York (USA) and Basel (Switzerland), 27 September 2012 – Lonza announced today that Intellect Neurosciences, Inc. (OTCBB:ILNS) awarded the future development and manufacture of the antibody drug conjugate CONJUMAB-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s CONJUMAB-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease. Intellect Neurosciences is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.

The new program is expected to include in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza. Intellect also plans to work with a number of independent specialized contract research organizations to evaluate the compounds produced by Lonza Chemical Manufacturing in Visp, Switzerland. Intellect‘s program is led by Dan Shochat, Ph.D., Intellect Neurosciences’ Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.

"CONJUMAB-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We anticipate improved efficacy compared to naked amyloid beta antibodies currently in clinical development for AMD. The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences, and we are very proud to be working with such a high caliber team at Lonza," said Dr. Daniel Chain, Chairman and CEO. "Based on recent discussions with global pharmaceutical companies that have expressed interest in the program, we see this program as a near-term opportunity for potential partnering for Intellect."

"Lonza looks forward to collaborating with Intellect Neurosciences on its CONJUMAB-A program," said Stefan Stoffel, Head of Lonza Chemical Manufacturing. "We have already generated a detailed road map for the optimization and manufacture of CONJUMAB-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

http://finance.yahoo.com/news/lonza-intellect-neurosciences-…
ChromaDex® Announces the Award of Two Method Validation Study Contracts from the Office of Dietary Supplements, National Institutes of ; Contract Awards "Demonstrate Recognition of ChromaDex Phytochemical Analytical Expertise" - Oct 29, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://photos.prnewswire.com/medias/appnb/authLogin.do?zAuth…

"IRVINE, Calif., Oct. 29, 2012 /PRNewswire/ -- ChromaDex® Corporation (CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today the award of two method validation study contracts from the Office of Dietary Supplements (ODS), National Institutes of Health (NIH). These awards were made as part of the contract ChromaDex has with the General Services Administration (GSA) -- Schedule 66: Scientific Equipment and Services, SIN 873-2: Chemical Testing and Analysis Services, Contract Number: GS-07F-0243W, Contract Period: March 1, 2010 to February 28, 2015.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

These contracts will create single laboratory validated methods for the quantitative determination of total silymarin content of milk thistle and of total curcuminoid content in turmeric. Having analytical tools to evaluate dietary supplement identity and purity is not only required under the new Current Good Manufacturing Practices (cGMPs) from the Food and Drug Administration (FDA), but is also a critical factor for assurance of public safety, developing and maintaining quality assurance standards in manufacturing and, ultimately, for meaningful efficacy testing of these products.

ChromaDex, in addition to its own expertise, will draw on the experience and knowledge of others in the botanical and dietary supplements industry to complete these two contracts. The goal of this work is to create methods that can be used to evaluate raw materials, extracts and finished products. Once completed, the methods developed under these contracts will be published.

Commenting on the announcement, Frank Jaksch, CEO and Founder of ChromaDex, stated, "We are honored to be awarded these contracts by the NIH and ODS, as they provide further recognition of ChromaDex's phytochemical analytical expertise and the long history of collaboration between ChromaDex and the NIH in the area of dietary supplement reference standards and analytical testing. With the implementation of cGMPs now in full force, the industry needs to have robust analytical methods that they can rely on, such as the ones that will be developed by ChromaDex under the two contracts."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694. "
ChromaDex® Acquires Spherix Consulting; Spherix Consulting "Brings Technical +Regulatory Services to Further Build ChromaDex's Offering of Science-Based Solutions" - Dec 3, 2012
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Dec. 3, 2012 /PRNewswire via COMTEX/ --ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today the completion of the acquisition of Spherix Consulting, Inc., a subsidiary of Spherix, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

As a result of the transaction, Spherix Consulting became a wholly-owned subsidiary of ChromaDex. Spherix Consulting will continue to maintain offices in the greater Washington, D.C. area. As a leader in scientific and regulatory consulting, Spherix Consulting has a well-established list of Fortune 1000 customers. The transaction is expected to result in an immediate increase in revenue for ChromaDex.

Spherix Consulting provides its clients in the food, supplement and pharmaceutical industries with effective solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations; and design and assessment of pre-clinical and clinical safety testing. Spherix Consulting specializes in regulatory submissions for food and dietary supplement ingredients (GRAS, NDIN, Food Additive Petitions, Novel Food Petitions). For its clients involved in drug development within the pharmaceutical industry, Spherix provides similar services as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and IND writing.

The acquisition will complement and expand ChromaDex's leadership in the reference standards and services business. By providing a more comprehensive suite of science-based and regulatory services, ChromaDex will to able to more efficiently advance products in the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical markets.

Commenting on the announcement, Frank Jaksch, CEO and co-Founder of ChromaDex, stated, "Spherix Consulting is a premier provider of product regulatory approval and scientific advisory services. Given the rapidly changing regulatory environment, these services have never been more critical for suppliers, manufacturers and retailers. By acquiring Spherix Consulting we provide this valuable expertise to better support our customers' product development outcomes."

Claire Kruger, who will continue as President of Spherix Consulting, added, "Together, Spherix Consulting and ChromaDex will provide a comprehensive platform of services for our clients that is both efficient and effective. Our unparalleled industry expertise and complementary offerings will provide our customers with enhanced services and better access to the information they need to make science-based decisions."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. "
ChromaDex® to Present @the RedChip Small-Cap Virtual Conference, on December 5th @2:45 p.m. EST - Dec 4, 2012
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
ChromaDex® to Distribute IsoLife Stable Isotope Labeled Phytochemicals, +Plant Products - Jan 22, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif. and WAGENINGEN, Netherlands, Jan. 22, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex") an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has signed a distribution agreement with IsoLife bv, which provides stable isotope labeled phytochemicals and plant products. These 13C- and 15N-labeled phytochemicals and plant products are used as tracers and internal standards for food & beverage, nutraceutical, pharmaceutical, cosmeceutical and environmental sciences research.

"The IsoLife agreement will add to ChromaDex's comprehensive and growing catalog, which contains more than 3,000 phytochemicals and 500 botanical reference materials," said Frank Jaksch , CEO and co-founder of ChromaDex. "By adding the IsoLife stable isotope materials to our portfolio, we continue our commitment to providing access to key materials to the research community, helping to facilitate important research for the Life Science industry."

Ton Gorissen and Ries de Visser, directors and founders of IsoLife, note the co-operation with ChromaDex is a natural extension of IsoLife's activities. "By using the excellent sales force of ChromaDex, we will be much better able to serve Life Science research needs in the overseas markets. The non-labeled and stable isotope-labeled products of both companies perfectly match and complement each other."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside; NutraGAC™, a Gac fruit powder rich in lycopene and beta-carotene; and pteroberry™, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.


About IsoLife:

IsoLife bv was established in 2005 as a spin-off company of Wageningen University & Research Center, The Netherlands. IsoLife develops, produces and sells uniformly stable isotope labeled (> 97 atom %) plant parts and their phytochemicals. Their stable isotope labeling facilities consist of fully computer controlled closed-system labeling chambers which are unique worldwide. IsoLife's products are used as tracers and internal standards in research and diagnostics in the Life Sciences by private companies and public research organizations worldwide. They are non-radioactive and allow non-invasive techniques that are completely safe and consumer, patient and environment-friendly. IsoLife has been identified by FEM Business Tech 25 as one of 25 young, innovative companies who 'shake the market with brilliant ideas.' "
ChromaDex® to Distribute LoGiCal®, a New Range of Reference Standards in the United States; Range "Offers a Segment of Solutions that are Fully ISO Guide 34 Certified, an Assurance that the Manufacturer's Standards are Produced Correctly +Competently" - Feb 7, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif. and TEDDINGTON, England, Feb. 7, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex") and LGC Standards announced today that they have signed an agreement for ChromaDex to distribute a new range of reference standards called LoGiCal®, which will focus on the forensic and clinical sectors and their line of pharmaceutical impurities standards. ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. LGC Standards is a provider of products and services to improve measurement and quality control within the laboratory and is a major division of U.K.-based LGC, whose LGC Science & Technology Division acts as the U.K. National Measurement Institute for chemical and bioanalytical measurements.

LoGiCal®, as a new product range focusing on the needs of forensic and clinical laboratories, will provide access to a wide variety of reference materials, including drugs of abuse, prescription drugs and drug metabolites. A segment of this product line is ISO Guide 34 certified, which ensures that all methods a manufacturer uses to certify their standards are validated and proven to be accurate, a new addition to the ChromaDex portfolio. This will add to ChromaDex's extensive current catalog that contains over 3,000 phytochemicals and 470 botanical reference materials that serve a wide variety of markets such as food & beverage, pharmaceutical, cosmeceutical, research organizations and governmental groups.

Frank Jaksch, CEO and co-founder of ChromaDex commented, "By adding the LoGiCal® reference standards to our portfolio of offerings, we further add to our ability to be a one-stop shop for our customers."

Dr. Keith Williams, Product Manager and Key Account Manager at LGC Standards, said, "We are delighted that ChromaDex is incorporating LoGiCal® products into their portfolio. The availability of these high quality reference materials will allow U.S. laboratories to meet their compliance needs."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside, NutraGAC™, a Gac fruit powder rich in lycopene and beta-carotene and pteroberry™, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.


About LGC Standards:

LGC Standards (www.lgcstandards.com) provides products and services to improve measurement and quality control within the laboratory, and is part of LGC, whose LGC Science & Technology Division acts as the UK National Measurement Institute for chemical and bioanalytical measurements. LGC Standards supplies over 100,000 products, including reference materials, pharmaceutical impurity reference standards (produced under ISO Guide 34 accreditation), biological standards and reagents, and proficiency testing. LGC Standards is headquartered in Teddington, Middlesex, UK. Its global centre for excellence in proficiency testing is located in Bury (Greater Manchester). LGC Standards has offices in France, Germany, Italy, Poland, Spain, Sweden, China, Russia, United Arab Emirates and the UK, a joint venture presence in India, and representatives in Brazil, Bulgaria, Czech Republic, Finland, Hungary, Ireland, the Netherlands, Romania, Turkey and the US.


About LGC:

LGC (www.lgcgroup.com) is the international science-based company and market leader in analytical, forensic, biotechnology and diagnostic services, as well as diagnostic products, proficiency testing and reference standards. LGC operates in a variety of international markets which underpin the safety, health and security of the public and the regulation of industry, for both public and private sector clients. LGC has four divisions - LGC Forensics, LGC Genomics, LGC Standards and LGC Science & Technology. The latter includes specialist laboratories delivering contracts for the Department for Business, Innovation and Skills (BIS) and supports LGC's designated role as the UK's National Measurement Institute for chemical and bioanalytical measurement.

Our operations are extensively accredited to international quality standards such as ISO/IEC 17025. With headquarters in Teddington, South West London, the LGC Group employs over 1,600 staff in 36 laboratories and centres globally. Privatised in 1996 and now majority-owned by funds managed by Bridgepoint, LGC was founded 170 years ago as the Laboratory of the Government Chemist - a statutory function maintained by LGC today. "
ChromaDex® Plans Strategic Sale of its BluScience™ Consumer Product Line, to NeutriSci International - Feb 23, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Feb. 25, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today it has entered into a letter of intent ("LOI") to sell its BluScience™ consumer product line to NeutriSci International ("NeutriSci"). The BluScience line of products can be found in over 15,000 retail locations across the United States.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

Frank Jaksch, CEO and Founder of ChromaDex stated, "By launching the BluScience consumer products, we achieved our primary goal of increasing the awareness of pTeroPure. We are excited to have found a strategic partner with strong nutraceutical consumer product marketing expertise to take the BluScience brand to the next level. We look forward to working with the NeutriSci team to make BluScience a tremendous success."

Mr. Keith Bushfield, NeutriSci President and CEO, stated, "We are pleased and excited that we were able to find such a strong strategic partner as ChromaDex. We feel ChromaDex has built a brand in BluScience that offers what consumers require – a clinically proven product line backed by strong scientific research and development. The consumer can be confident in both the efficacy and safety of this amazing natural line of health and wellness products. In addition to the North American market, I am excited to introduce BluScience globally starting with our vast network in Southeast Asia."

Under the terms of the LOI, upon closing the total transaction is valued at approximately $6.0 million and will consist of a combination of cash, senior secured debt and an ownership interest in NeutriSci. ChromaDex will continue to generate revenue through a royalty on future net sales of BluScience products as well as a supply agreement with NeutriSci for its patented pTeroPure pterostilbene, which will continue to be the key active ingredient in the BluScience product line. ChromaDex will retain all rights and ownership to its pTeroPure pterostilbene. NeutriSci paid a non-refundable $250,000 deposit to ChromaDex, which will be applied toward the total consideration to be paid. Closing is expected to occur before March 31, 2013 upon satisfaction of various closing conditions.

Closing of the proposed transaction is subject to numerous usual and customary conditions including, without limitation, further due diligence and entering into a definitive asset sale agreement as well as financing conditions. There can be no assurance that the transactions contemplated by the LOI will be consummated or that any of the conditions to closing will be satisfied. The LOI and this announcement do not constitute an offer to buy, or solicitation of an offer to sell, any securities of ChromaDex or NeutriSci.

Mr. Jaksch continued, "The sale of our BluScience product line will allow ChromaDex to focus on selling and marketing our pTeroPure ingredient, as well as accelerate the development of our novel ingredients pipeline. We continue to be confident about our business strategy of identifying early novel compounds, securing intellectual property, developing commercially viable production processes, investing in clinical data and executing a commercial launch."


About BluScience:

ChromaDex® made a strategic decision to create and launch the BluScience™ product line as a means of generating awareness for its patented and proprietary pTeroPure®. The nationwide launch of BluScience in retail outlets began in earnest in early 2012, and today BluScience is available in more than 15,000 retail locations as well as through prominent online retailers. The BluScience line is currently comprised of:

- EternalBlu – supports cellular health and has anti-aging properties
- HeartBlu – helps maintain healthy cholesterol levels and supports cardiovascular health
- MemoryBlu – supports concentration, memory and cognitive function
- TrimBlu – helps control appetite and supports healthy metabolism
- Blu2Go – provides a sustained energy boost and supports focus & mental clarity


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 35% cyanidin-3-glucoside, NutraGAC™, a Gac fruit powder, pteroberry™, a natural pterostilbene and organic berry blend, and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about ChromaDex, please call 949-600-9694.


About NeutriSci International:

NeutriSci International Inc. is an Alberta corporation working as a leader in the innovation, production and formulation of science-based and clinically proven nutraceutical products. Established in 2009, NeutriSci has focused on the market development of several breakthrough nutraceutical products; with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense and men's prostate and sexual health. NeutriSci distributes and manufactures such products as Vendrome, Repose, Veaya Lyfe and ZEO-8. Vendrome is a men's dietary supplement designed to combat certain effects of aging in older men and provide improved vitality in younger men. Repose is a liquid sleep therapy system designed to help alleviate insomnia. LYFE is a health-enhancing natural juice drink meant to help support the body's ability to fight off diseases. Zeo8 is a detoxification drink meant to help trap and expel from the body a variety of toxins like mercury, lead and arsenic, biotoxins, pesticides and radioactive material.

NeutriSci has also developed a proprietary marketing system called Direct Viral MarketingTM or D.V.M.TM. D.V.M.TM is a marketing system utilizing a revolutionary referral platform designed to combine the power of direct marketing with a non-invasive referral system. Management believes that D.V.M.TM is a marketing system that could change the future of Network Sales. "
ChromaDex® Adds to Its Exclusive Worldwide Patent Rights for Nicotinamide Riboside(NR), with Washington University Agreement - Mar 8, 2013

+ NR is a Newly Discovered Vitamin +is a Natural Metabolite of Niacin (Vitamin B3) -

+ Found in Milk, NR is Linked to Numerous Health Benefits -
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., March 8, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today it has licensed from Washington University exclusive worldwide patent rights related to the recently discovered vitamin, Nicotinamide Riboside (NR). The patent rights cover the use of NR for the prevention or treatment of neuropathies caused by axon degeneration.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

Axon degeneration is a common feature of many neurological ailments including mechanical, chemical or thermal injury, herpes, diabetes, ischemia or stoke, amyotrophic lateral sclerosis (ALS), glaucoma, rheumatoid arthritis, lupus, AIDS and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease1. Axon degeneration can also be caused by chemotherapy induced neuropathy or "CIN". Symptoms of neuropathy include weakness, numbness, burning and tingling, as well as pain in arms, legs and/or feet which can be debilitating. Neuropathies affect more than 20 million of people in the U.S.

The license was developed from research by Jeffrey Milbrandt, M.D., Ph.D., a James S. McDonnell Professor and head of the Department of Genetics at Washington University School of Medicine in St. Louis. His studies have focused on nicotinamide adenine dinucleotide (NAD), of which NR is an important precursor.

Milbrandt commented, "NAD biology has gained added importance in recent years due to its central role in controlling the activity of sirtuins, enzymes that are linked to regulation of metabolism as well as longevity. Interest is increasing in the roles of NAD biosynthetic enzymes and their substrates, such as NR, in the pathophysiology and treatment of neuropathies and neurodegenerative diseases, diabetes, cancer and inflammation."

This is the third acquisition made by ChromaDex of worldwide patent rights associated with NR. In July 2012, the Company licensed from Dartmouth College exclusive rights to several patents related to NR that include rights for human uses of NR as well as methods to produce NR via fermentation of engineered yeast strains. In July 2011, ChromaDex licensed a patent from Cornell University for a method for synthesizing NR in a cost effective, commercially-viable manufacturing process for large scale production.

Frank Jaksch, CEO and founder of ChromaDex, stated, "The acquisition of the Washington University NR patent rights is an important addition to our growing patent portfolio pertaining to NR. We believe our ownership of these patent rights creates a significant and meaningful barrier to entry for would-be competitors in the NR market."

Mr. Jaksch continued, "With the recent favorable published research on the significant health benefits of NR and the anticipated, forthcoming published research studies from several prestigious universities and research institutes, we believe NR is poised to become one of our most successful and valuable patented and proprietary ingredients to date."


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and blocking muscle degeneration.

Researchers have shown that NR enhances levels of NAD in the mitochondria of animals. NAD is arguably the most important cellular co-factor for fuel utilization and allows sugars, fats and proteins to be converted into energy. Mitochondria are thought to play a part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Groups worldwide continue seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diet and improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 35% cyanidin-3-glucoside; NutraGAC™, a Gac fruit powder; pteroberry™, a natural pterostilbene and organic berry blend; and is in the process of developing Nicotinamide Riboside (NR), a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about our products, visit www.chromadex.com or call 949-600-9694.


About Washington University:

Washington University, established by special act of the Missouri General Assembly on February 22, 1853, is a private, research university located in St. Louis. The University's mission is to discover and disseminate knowledge, and protect the freedom of inquiry through research, teaching, and learning. "
Dr. Nancy Booth of Spherix Consulting - a Division of ChromaDex® - Appointed to American Botanical Council Advisory Board - Mar 21, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., March 21, 2013 /PRNewswire/ -- Spherix Consulting, a division of ChromaDex® Corporation (OTCQB:CDXC) ("ChromaDex"), announced today that its Senior Science Director, Dr. Nancy Booth, has been appointed to the advisory board of the American Botanical Council (ABC). ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries and has been a member of the ABC for more than eight years.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

While serving on the Advisory Board, Dr. Booth will be volunteering her time to peer review articles that appear in HerbalGram, HerbalEGram, HerbClips and/or various ABC publications. Additionally, HerbalGram editors typically seek feedback and advice from Advisory Board members on issues such as research questions, article ideas, ABC policies and book reviews. Dr. Booth's diverse training in the areas of organic/bio-organic chemistry, pharmacognosy, natural products, dietary supplements and cancer will aid in these duties during her term on the ABC Advisory Board.

Dr. Booth's primary areas of expertise are in the scientific evaluation of botanical dietary supplements, development of high-throughput screening assays and drug discovery. She also has experience in anticancer signal transduction pathways utilizing death receptors, estrogenic phytochemicals and optimizing in vitro bioassays for use with natural products. Her credentials include a Cancer Research Training Award Postdoctoral Fellow from NCI-Frederick, Frederick, MD and a Ph.D. in Pharmacognosy from the University of Illinois at Chicago, Chicago, IL.

"We are very pleased that Dr. Booth has been appointed to this important role with the ABC," said Frank Jaksch, CEO and Founder of ChromaDex. "Throughout her career, Dr. Booth has demonstrated a commitment to advancing the natural products industry and this honor recognizes her expertise and leadership. ChromaDex is a proud supporter of the ABC and Dr. Booth's appointment will give her a new platform to convey her knowledge to a wider audience in support of natural product innovation."


About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40 percent cyanidin-3-glucoside; NutraGAC™, a Gac fruit powder rich in lycopene and beta-carotene; and pteroberry™, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. "
ChromaDex® Reports `12 Full-Year Results, +Closes Strategic Sale of Its BluScience™ Consumer Product Line - Mar 29, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
ChromaDex® Introduces New Caffeine Ingredient Technology, PURENERGY™; PURENERGY "Shown to Have 6-8 Times :eek: Longer Half-life, versus Caffeine Alone" - Apr 1, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://finance.yahoo.com/news/Frost-Sullivan-Recognizes-iw-3…

IRVINE, Calif., April 1, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the introduction of PURENERGY™, a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene that forms a unique crystalline structure having significant advantages as compared to caffeine alone.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

PURENERGY demonstrated in animal models a 6-8 times longer half-life as compared to caffeine alone.1 This suggests that PURENERGY may provide longer sustained energy and alertness with a more gradual finish, preventing the "crash" typically experienced when ingesting caffeinated products. :eek: :eek: This patented new ingredient technology should allow formulators of caffeinated products the opportunity to reduce the total amount of caffeine without :eek: affecting the consumers' product experience.

Frank Jaksch, co-founder and CEO of ChromaDex stated, "There has been and will continue to be tremendous demand for caffeinated products across many markets including energy, functional beverages, sports nutrition and weight loss. We believe that PURENERGY offers a responsible, next-generation alternative to heavy doses of caffeine. PURENERGY balances the consumer's desire to feel the effects of caffeine with the pressure consumer product companies are under to reduce caffeine levels in finished products."


Recently, highly caffeinated products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts caffeine. Specifically:

- In March 2012, a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine.

- In October 2012, U.S. Senator Richard Blumenthal (D-CT) and U.S. Senator Dick Durbin (D-IL) challenged the Food and Drug Administration (FDA) to quickly identify and recommend remedies for weaknesses and loopholes in current law that are exploited by energy drink manufacturers in order to avoid oversight and offer products containing additives and high levels of caffeine that have not been proven safe.

- In December 2012, Canada's regulatory agency, Health Canada, capped the amount of caffeine in energy drinks.

- In March 2013, a group of 18 doctors, researchers and public health experts jointly urged the FDA to take action on energy drinks to protect adolescents and children from the possible risks of consuming high amounts of caffeine.

- In March 2013, the American Heart Association Meeting Report cited energy drinks may increase blood pressure and disturb the heart's rhythm.


Given the co-crystal formulation of caffeine with pTeroPure, PURENERGY also has additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is a 99 percent pure, nature-identical pterostilbene with seven patents pending or issued. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. PURENERGY and pTeroPure are manufactured exclusively for ChromaDex by Laurus Labs, one of the leaders in API manufacturing.

1 Data on file


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and nicotinamide riboside, a novel next-generation B-vitamin currently under development. To learn more about ChromaDex please visit www.chromadex.com. "
ChromaDex® Initiates First Human Clinical Study for Its New Caffeine Ingredient Technology, PURENERGY™, Caffeinated Energy Products "under Increased Regulatory +Political Scrutiny" - Apr 18, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., April 18, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study in the U.S. for PURENERGY™.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

PURENERGY is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene that forms a unique crystalline structure having superior benefits as compared to the two individual components alone. Recently, caffeinated energy products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts of caffeine. This patented new ingredient technology should allow formulators of caffeinated energy products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.

The human study is intended to confirm an earlier animal study which showed PURENERGY had a 6-8 times longer half-life as compared to caffeine alone.1 The results of the animal study suggest that PURENERGY may provide longer sustained energy and alertness with reduced amounts of caffeine and without the "crash" typically experienced when ingesting caffeinated energy products.

The clinical trial is designed to determine the safety, relative bioavailability and pharmacokinetics of PURENERGY as compared to pterostilbene and caffeine alone. The start of this trial in the U.S. follows the recent commercial launch of PURENERGY.


Frank Jaksch, co-founder and CEO of ChromaDex stated, "The study will provide valuable insight about the benefits of PURENERGY and be an important addition to the previously successful animal study. We believe the introduction of PURENERGY is timely given the current regulatory scrutiny of caffeinated energy products."

Given the co-crystal formulation with pTeroPure, PURENERGY also has additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is a 99 percent pure nature identical pterostilbene with seven patents pending or issued. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. PURENERGY and pTeroPure are manufactured exclusively for ChromaDex by Laurus Labs, one of the leaders in API manufacturing.

1 Data on File


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and nicotinamide riboside, a novel next-generation B-vitamin currently under development. To learn more about ChromaDex please visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 45.684.155 von Popeye82 am 24.10.13 04:28:39
ChromaDex® Introduces NIAGEN™ - The "1st :eek: +Only :eek: :eek: Commercially Available Nicotinamide Riboside"; Sometimes Referred to as the "Miracle Molecule," NR is a Newly Discovered Vitamin :eek: ; a More Potent No-Flush Version of Niacin; NR is " "Linked" to Multiple Health Benefits Associated with Improved Mitochondrial Function", Including Obesity, Anti-aging +Cardiovascular Health - May 29, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., May 29, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the launch of NIAGEN™, its novel, patented, branded nicotinamide riboside (NR).

(Logo: http://photos.prnewswire.com/prnh/20130529/LA22032LOGO)

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

ChromaDex's NIAGEN™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

NIAGEN™ may have tremendous appeal to the approximately 150 million Americans who are obese or over weight as well as the 75 million aging baby boomers in the U.S. – both of which are actively seeking new dietary supplement solutions for obesity or healthy aging. These large segments of the U.S. population continue to fuel the growing multi-billion dollar dietary supplement markets.

NIAGEN™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.


Frank Jaksch, Founder and CEO, states "By solving the immense challenge of producing NR on a commercially viable scale, we have achieved the first step in unlocking the potential of this new vitamin. The formal launch of NIAGEN™, our branded nicotinamide riboside, will immediately allow dietary supplement, and food & beverage companies to include NIAGEN™ in product formulations.

Jaksch continues, "We are in the final stages of completing the design of our first human clinical study for NIAGEN™. Additionally, we continue to collaborate with several universities and research institutes who have ongoing research activities designed to validate the tremendous health benefits of NR as well as create a strong commercial platform of health claims."


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (Vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and blocking muscle degeneration.

Researchers have shown that NR enhances levels of NAD in the mitochondria of animals. NAD is arguably the most important cellular co-factor for fuel utilization and allows sugars, fats and proteins to be converted into energy. Mitochondria are thought to play a part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Groups worldwide continue seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diet and improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less :eek: weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."



About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 45.691.967 von Popeye82 am 25.10.13 01:25:40
High Performance Nutrition Introduces a New Product, N(R), "Featuring NIAGEN™ to Support Neuroprotection in Contact Sports"; N(R) To Be Launched @National Athletic Trainer's Association 64thAnnual Meeting & Clinical Symposia - Jun 25, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://hpnformula1.com/store/Nr/

"IRVINE, Calif., June 25, 2013 /PRNewswire/ -- High Performance Nutrition (HPN) today announced the launch of N(R)TM, an innovative daily nutritional supplement designed to protect against axon degeneration damage or trauma sustained in the course of playing contact sports :eek: . N(R) is one of the first commercially available products to feature the ingredient NIAGENTM from ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.

ChromaDex Inc. developed its breakthrough ingredient NIAGEN as the patent-protected and first and only commercially available brand of nicotinamide riboside, which is known to boost levels of NAD+ in the cells. Studies have demonstrated that increasing the production of NAD+ can protect against axon degeneration caused by mechanical or neurological injury.

Recent studies have demonstrated that the head trauma that occurs in contact sports can lead to brain damage. The prevalence of repeated blows to the head in contact sports such as football, soccer and hockey has raised the concern of scientists, public officials, athletes and parents. Sean Torbati, CEO and president of HPN, believes in the importance and responsibility of protecting the health of athletes, especially that of America's youth, from debilitating brain injuries. His company has tapped into NIAGEN as a protective measure with the introduction of N(R)TM.


"N(R) addresses the recent discovery that protection from brain injury should start off the field before it continues on the field with barriers such as helmets," said Torbati. "About three million children younger than 14 play organized tackle football in the United States, not to mention the millions playing competitively in high school, college and beyond, as well as the millions more engaging in other sports in which helmets are worn such as baseball, lacrosse, hockey or even horseback riding. Recent findings that athletes playing soccer are also at risk for brain injury "further demonstrates the "potential" for N(R) to be used by athletes worldwide"."

Frank Jaksch, founder and CEO of ChromaDex, states "HPN is forging into a new and innovative market with N(R) by aiming to prevent or delay axonal degeneration before trauma even :eek: occurs. Backed by scientific evidence and patented nutrition technology [US7776326], N(R) is "poised to revolutionize :eek: how players of contact sports think about potentially protecting themselves in the long run.""

Sean Torbati further comments, "An asset as important as the human brain deserves the most protection possible, not just when you step onto the field and put on that helmet. It's a no-brainer."

For more information, please visit http://hpnformula1.com/store/Nr/


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue their seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diets and improvement of blood glucose and insulin sensitivity.


About HPN

HPN LLC was founded in 2010 with its mission being to set a new standard for quality, safety, innovation and effectiveness in the natural sports nutrition industry. The "no compromises" approach to every aspect of HPN's product development, manufacturing and testing sets the company apart from the rest of the sports nutrition category.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure®; pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
ChromaDex® Awarded Small Business Technology Transfer Phase I Grant By National Science Foundation; $225.000 Awarded to Develop the Technology for a Microbial Approach to Catechin Production - Jun 27, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., June 27, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has been awarded a $225,000 Small Business Technology Transfer (STTR) grant by the National Science Foundation (NSF).

The grant will support research conducted in collaboration with Rensselaer Polytechnic Institute in Troy, N.Y., under the topic of Enhancing the Bioeconomy using Emerging Biological Technologies (EBBT). The purpose of the research is to develop a microbial technique for producing catechins for commercial use in dietary supplement, nutraceutical, food, beverage and cosmetic products.

The project, entitled "STTR Phase I: Microbial Production of Catechins," will set the stage for understanding the biosynthetic pathway and prove the viability of fermentation technology for selectively manufacturing catechins.

Primarily found in green tea and cocoa, cathechins form the basis of a number of antioxidant compounds such as epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and epigallocatechin gallate (EGCG). Due to its low percentage in natural products such as green tea, it is not economically viable to isolate commercial quantities of catechins from these materials. This microbial fermentation strategy will help enhance the production of such beneficial catechins through a bioeconomic approach utilizing principles of synthetic biology, metabolic engineering and other emerging biotechnologies.

"We have been on the forefront of creating various unique compounds via a microbial approach, and we are pleased that the NSF is continuing its support for this type of research through the STTR grant," said Frank Jaksch, co-founder and CEO of ChromaDex. "This is a natural extension of the Phase I and Phase II SBIR work that ChromaDex did in the area of anthocyanin production using fermentation. Catechins are strong natural antioxidants which have applications in the dietary supplement and food markets as a natural additive to extend shelf life."

ChromaDex and Rensselaer Polytechnic Institute will collaborate during this yearlong STTR program to develop the microbial strains necessary to demonstrate the viability of this approach to catechin production.

STTR is a program that expands funding opportunities in the federal innovation research and development arena. Central to the program is expansion of the public/private sector partnership to include joint venture opportunities for small businesses and nonprofit research institutions. The unique feature of the STTR program is the requirement for the small business to formally collaborate with a research institution in Phase I and Phase II. STTR's most important role is to bridge the gap between performance of basic science and commercialization of resulting innovations.

When the program is completed, ChromaDex plans to add catechins to its portfolio of novel ingredients to market to dietary supplement, food & beverage, animal health and cosmetic companies, working to meet growing consumer and trade demands for natural ingredients in the marketplace.


About National Science Foundation Funding

The National Science Foundation funds research and education in most fields of science and engineering. This is accomplished through grants and cooperative agreements to more than 2,000 colleges, universities, K-12 school systems, businesses, informal science organizations and other research organizations throughout the United States.

NSF receives approximately 40,000 proposals each year for research, education and training projects, of which approximately 11,000 are funded. The SBIR program is a highly competitive program that encourages small businesses to explore their technological potential and provides the incentive to profit from commercialization.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure®; pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin; and Niagen™, its recently launched branding nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
Fox Business ChromaDex RedChip Money Report - Jun 27, 2013

Antwort auf Beitrag Nr.: 45.691.967 von Popeye82 am 25.10.13 01:25:40
Scripps Research Institute +ChromaDex® To Collaborate on Niagen™ Nicotinamide Riboside Research; ChromaDex's Niagen™ is the 1st +Only Commercially Available Nicotinamide Riboside - Jul 1, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., July 1, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with The Scripps Research Institute ("TSRI") whereby ChromaDex will provide TSRI with quantities of its recently launched Niagen™ nicotinamide riboside (NR).

TSRI researchers have been studying the relationship between dysfunction of mitochondria, the energy-producing parts of the cell, and various life-threatening diseases. More specifically, the studies have focused on whether disease-affected cells change the balance between nicotinamide adenine dinucleotide, or NAD+, which has a positive charge, and NADH, an electrically neutral form of the molecule.

TSRI research has shown that therapeutic normalization of the NAD+/NADH balance can prevent the disease progression. The results translate into a new therapeutic strategy: enhancement of the NAD+/NADH balance through treatment with NAD+ precursors, such as nicotinamide riboside.

Commenting on the announcement, Frank Jaksch, ChromaDex founder and CEO, states "We are pleased to partner with TSRI on such important and exciting research. Their studies will add to the growing amount of research showing of the important health benefits of nicotinamide riboside, and portends one of the possible pharmaceutical uses for Niagen™."


ChromaDex's Niagen™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

Niagen™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.



About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue their seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diets and improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About The Scripps Research Institute:

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and Niagen™, its recently launched branding nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 45.691.967 von Popeye82 am 25.10.13 01:25:40
ChromaDex® Announces Deal For Its Recently Launched Niagen™ Nicotinamide Riboside With Thorne Research; Thorne Research to Market Niagen™ to the Healthcare-Practitioner Channel; ChromaDex's Niagen™ is the 1st +Only Commercially Available Nicotinamide Riboside - Jul 8, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., July 8, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, today announced a three-year marketing deal worth at least $3.5 million with Thorne Research Inc. for ChromaDex's recently launched Niagen™, its novel, patented branded nicotinamide riboside (NR) ingredient.

Under the terms of the agreement, Thorne Research receives marketing rights for Niagen™ for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the United States and Canada. ChromaDex will receive a royalty on sales of Thorne Research products that will contain Niagen™. In addition, Thorne Research will collaborate with ChromaDex on future human clinical trials of Niagen™.

"Mitochondrial energy production is critical for efficient metabolism of fats and carbohydrates, weight management, athletic performance, cardiovascular health and neuroprotection," said Robert Rountree, M.D., Chief Medical Officer of Thorne Research. "Research has shown that oral nicotinamide riboside, a compound naturally found in the diet, can significantly optimize mitochondrial function by increasing intracellular levels of NAD+. In addition to improving the overall redox state of the cell, an increase in NAD+ results in activation of SIRT1 and PGC-1alpha, cellular proteins that play a major role in mitochondrial biogenesis, glucose regulation and protection against age-related disease. Studies have shown that nicotinamide riboside increases muscle endurance, protects nerve cells from injury, improves insulin sensitivity, lowers serum cholesterol and limits diet-induced obesity. Nicotinamide riboside also represents the next generation of vitamin B3, providing the benefits of niacin but without the disturbing flush that impairs patient compliance."

Paul Jacobson, CEO of Thorne Research, stated, "We believe Niagen™ is one of the most :eek: exciting new ingredients to be introduced in the nutritional supplement market in the past decade :eek: :eek: :eek: . We are thrilled to be the first manufacturer in our market sector to be able to incorporate this ingredient, and we plan on having a series of first-to-market products that incorporate Niagen™."

Frank Jaksch, ChromaDex founder and CEO, stated, "Our recently announced launch of Niagen™ has resulted in numerous inquiries from leading companies in the nutritional supplement industry. We are proud to have Thorne Research, a highly regarded industry innovator, as our first channel partner for Niagen™, our branded nicotinamide riboside."

ChromaDex's Niagen™ has the potential to be a next-generation niacin (vitamin B3) and become a part of the portfolio of B-vitamin ingredients included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula and food and beverage products.

Niagen™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, increased mitochondrial activity, resistance to negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and blockage of muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important role in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists will see increased longevity as well as other health improvements. Researchers worldwide continue to make seminal discoveries in providing evidence for the unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high-fat diets and improvement of blood glucose and insulin sensitivity.

A recent study by researchers at Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne (Switzerland) found that mice on a high-fat diet fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice not fed NR, none of the NR-treated mice had indications they were developing diabetes and they had improved energy and lower cholesterol levels, all with no side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About Thorne Research:

Since 1984, Thorne Research has set the standard for exceptional quality manufacturing and formulation of premium hypoallergenic nutritional supplements available through licensed health-care practitioners. With more than 400 products, Thorne Research is recognized by health-care practitioners as a leader in providing nutritional supplements of the highest quality and purity. Through recent acquisitions and joint ventures, Thorne Research now offers product lines that address the nutritional support of cancer patients, cognitive and brain health and cardiovascular health, in addition to a product line for high performance athletes; a comprehensive product line of organic, non-GMO skin-care products; and related supportive practice management programs. With locations in Sandpoint, Idaho, and New York, New York, Thorne Research operates a state-of-the-art manufacturing facility and employs more than 250 people. Further information on Thorne Research is available at www.thorne.com.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin; and Niagen™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex visit www.chromadex.com. "
ChromaDex® Enters into Agreement with Beckman Research Institute of City of Hope to Supply pTeroPure™ Pterostilbene for Cancer Research - Jul 29, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., July 29, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Beckman Research Institute of City of Hope ("BRICOH") whereby ChromaDex will provide BRICOH with quantities of its branded pTeroPure™ pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.

According to the Center for Disease Control, over 300,000 women are diagnosed annually with breast, ovarian or uterine cancer. Second only to skin cancer, breast cancer is the most-common cancer among women.
1


Commenting on the announcement, Frank Jaksch, ChromaDex founder and CEO, states, "By providing materials to BRICOH for preclinical studies, we will learn more about the potential of pTeroPure's application in cancer. This relationship will complement our ongoing partnership with UC-Irvine, where we are supporting ongoing research on pTeroPure's use for nonmelanoma skin cancer."

Pterostilbene is an antioxidant that is primarily found in blueberries. Studies suggest that pterostilbene exhibits the hallmark characteristics of an effective anticancer agent based on its antineoplastic properties in several common malignancies. In vitro models have shown that pterostilbene inhibits cancer growth through alteration of the cell cycle, induction of apoptosis and inhibition of metastasis. In vivo, pterostilbene inhibits tumorigenesis and metastasis with negligible toxicity. Pterostilbene has also been shown to be effective as an inducer of antioxidant capacity in multiple cancer cell lines that may facilitate its function as an anticarcinogenic compound. Additionally, preliminary studies show that pterostilbene exhibits much greater bioavailability compared with other stilbene compounds; however, the exact pharmacologic mechanism of pterostilbene and its effects in humans are still under investigation.2


1 Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs.

2 Source: Denise McCormack MD, David McFadden MD, Journal of Surgical Research, Volume 173, Issue 2 , Pages e53-e61 , April 2012


ABOUT CITY OF HOPE:

City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with clinics in Antelope Valley and South Pasadena. It is ranked as one of "America's Best Hospitals" in cancer by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org or follow City of Hope on Facebook, Twitter, YouTube or Flickr.


ABOUT BECKMAN RESEARCH INSTITUTE:

Beckman Research Institute of City of Hope is the first of only five Beckman Research Institutes established by funding from the Arnold and Mabel Beckman Foundation. Researchers there are responsible for fundamentally expanding the world's understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes. Its breakthroughs in the areas of recombinant DNA technology, gene therapy and monoclonal antibodies are testaments to the culture of collaboration that inspires and informs its work.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and Niagen™, its recently launched branding nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
ChromaDex® Acquires New Exclusive Worldwide Patent Rights for pTeroPure® Pterostilbene Relating to Skin Care; Company also Acquires Right of 1st Refusal for Combined Use of Pterostilbene and Quercetin for the Prevention +/or Treatment of Skin Cancer - AUg 5, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Aug. 5, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed from Green Molecular, S.L. exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.

The acquisition brings the total number of patents and patents pending relating to pterostilbene owned by ChromaDex to eight. This is the second acquisition made by ChromaDex of worldwide patent rights for pTeroPure associated with skincare. In September 2011, the Company entered into an agreement with the University of California, Irvine, for the exclusive rights to a joint patent application filed by ChromaDex and the University.

According to Mintel research, it is anticipated that the U.S. market for skincare will reach almost $5 billion in 2013, with expected continued growth due to demand for anti-aging products. Companies are seeking innovative skincare solutions for their customers that are backed by science and protected by intellectual property.

Frank Jaksch, founder and CEO of ChromaDex states, "We intend to continue our strategy to build intellectual property around our ingredients. By building a robust skincare IP portfolio, we are positioning to become a meaningful provider of patent protected innovative ingredient technologies to this growing multi-billion dollar market place."

Dr. Jose M. Estrela, research director of Green Molecular, commented, "I am excited to have this collaboration with ChromaDex. Pterostilbene, as well as its possible association with other structurally-related natural polyphenols, has multiple applications in Biomedicine (see e.g. Estrela JM et al. Pterostilbene: Biomedical applications. Crit Rev Clin Lab Sci. 2013 May;50(3):65-78). Working with ChromaDex will allow for pterostilbene's cosmetic and pharmaceutical applications in skin care and pathology to reach the market."

pTeroPure®, ChromaDex's branded nature identical form of pterostilbene, is an antioxidant found in blueberries and was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. In September 2012, ChromaDex announced findings from a Phase 2/3 trial at the University of Mississippi Medical Center demonstrating that pTeroPure significantly reduced blood pressure in adults. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols -- an antioxidant phytochemical that tends to prevent or neutralize the damaging effects of free radicals -- allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic disorders. The amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin; and Niagen™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex visit www.chromadex.com.


About Green Molecular, S.L.:

Green Molecular is a spin-off company promoted by Cross Road Biotech (www.crbinverbio.com), a VC focused in life sciences, and the University of Valencia (Spain). Green Molecular working aim is focused on the development of the health benefits of natural polyphenols. Since its foundation in 2009, the company´s R&D has been focused on cancer prevention and treatment, as well as skin care applications. Nevertheless the company is interested in further expanding its patent portfolio based on the multiple biomedical applications of these natural compounds. "
ChromaDex® Reports Results, for the 2nd Quarter `13 - Aug 13, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Aug. 13, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the second quarter ended June 29, 2013.

For the three months ended June 29, 2013, ChromaDex reported revenue of $2,706,896, an increase of 1% as compared to $2,670,611 for the same period in 2012. The core standards, contract services and ingredients segment generated net sales of $2,504,372 for the three months ended June 29, 2013. This is an increase of 16%, compared to $2,150,585 for the same period in 2012. This increase was largely due to increased sales of analytical testing and contract services. The retail dietary supplement products segment did not have any sales for the three months ended June 29, 2013 as the Company sold its BluScience product line on March 28, 2013. For the same period in 2012, the retail dietary supplement products segment generated net sales of $520,026. The scientific and regulatory consulting segment, which is operated by the Company's subsidiary Spherix Consulting, Inc., generated net sales of $202,524 for the three months ended June 29, 2013. We did not have the scientific and regulatory consulting segment for the same period in 2012. The net loss attributable to common stockholders for the quarter ended June 29, 2013 was $989,722, or $0.01 per basic and diluted share, as compared to a net loss of $3,993,957, or $0.04 per basic and diluted share, for the same period in 2012. The net loss for the quarter ended June 29, 2013 is largely due to the share-based compensation expense. The non-cash, share-based compensation expense related to stock options and other share-based compensation for the second quarter of 2013 was $376,759. Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of decreasing the Company's net loss for the quarter ended June 29, 2013 to $612,963. As of June 29, 2013, cash, cash equivalents and marketable securities totaled approximately $826,631.


Recent Company highlights include:

- In May, the Company launched its novel, patented NIAGEN™, the first and only commercially available nicotinamide riboside, a precursor to NAD+. NIAGEN™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

- In June, High Performance Nutrition introduced a new product N(R)™, featuring NIAGEN™ to support neuroprotection in contact sports. N(R)™ is a nutritional supplement designed to protect against axon degeneration damage or trauma sustained in the course of playing contact sports. N(R)™ in one of the first commercially available products to feature the ingredient NIAGEN™.

- In July, the Company entered into an agreement with The Scripps Research Institute ("TSRI") whereby the Company will provide TSRI with quantities of Niagen™ nicotinamide riboside for research purposes. TSRI's studies will add to the growing amount of research showing many of the important health benefits of nicotinamide riboside, and portends possible pharmaceutical uses for Niagen™.

- In July, the Company entered in a three-year supply agreement with Thorne Research, Inc. ("Thorne") pursuant to which Thorne shall purchase and market the Company's patented nicotinamide riboside which is branded as NIAGEN™. Under the terms of the agreement, Thorne received marketing rights for NIAGEN™ for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the United States and Canada, provided that Thorne purchases a minimum of $3.5 million of NIAGEN™ product over the next three years.

- In July, the Company entered into an agreement with Beckman Research Institute of City of Hope ("BRICOH") to provide BRICOH with quantities of its branded pTeroPure™ pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.

- In August, the Company licensed from Green Molecular S.L. exclusive worldwide patent rights related to the use of pterostilbene for the prevention or treatment of skin diseases, damages, or injuries, as well as the combined use with quercetin for the production of melanoma skin cancer treatment medicine. The acquisition brings the total number of patents and patents pending relating to pterostilbene owned by ChromaDex to eight.

- In August, the fast-growing sports nutritional company, MusclePharm, announced that the new formulation of its award-winning pre-workout product, ASSAULT™, includes ChromaDex's PURENERGY™.


Upcoming Milestones:

- The Company expects to announce results of its previously announced first human clinical study in the U.S. for its PURENERGY™, a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene that forms a unique crystalline structure having benefits as compared to the two individual components alone. The human study is intended to confirm an earlier animal study which showed PURENERGY had a significantly longer half-life as compared to caffeine alone.

- The Company expects to initiate in October 2013 its first human clinical study on NIAGEN nicotinamide riboside. The pharmacokinetics (PK) study on NIAGEN will measure its effectiveness as a precursor to NAD+, a coenzyme that has crucial roles in many biochemical and biologic processes.


Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "After years of planning and substantial investment, our unique business strategy of identifying and commercializing novel, patented ingredient technologies is beginning to show dramatic results. We have commercialized and branded four novel, patented ingredients – NIAGEN nicotinamide riboside, PURENERGY, pTeroPure® pterostilbene and ProC3G – each of which have the prospects of becoming significant value drivers for our shareholders. The interest level in our ingredient portfolio from consumer product companies, ingredient companies, pharmaceutical companies and esteemed universities has exceeded our expectations."

Mr. Jaksch continued, "The initial interest in PURENERGY has been significant given the recent regulatory, political and media concerns surrounding added caffeine in consumer products. Separately, our first human trial on NIAGEN could have meaningful consequences given the significant level of research and interest in NAD+ precursors."


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and Niagen™, its recently launched branding nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 45.691.953 von Popeye82 am 25.10.13 01:12:25
Clinical Study Demonstrates ChromaDex's Caffeine Alternative, PURENERGY™, Delivers 30% More Caffeine, Stays in the Blood Stream Longer +is Absorbed More Slowly than Ordinary Caffeine; National Survey Shows 60 Percent of Americans Are Seeking a Caffeine Alternative That Reduces Caffeine Consumption without Sacrificing Desired Energy Boost - Sep 25, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Sept. 25, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the results of a cross-over clinical evaluation of its PURENERGY™ caffeine alternative - a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene, a potent anti-oxidant found in blueberries.

(Photo: http://photos.prnewswire.com/prnh/20130925/NY86068-INFO )

Based on the clinical evaluation, PURENERGY™ provides formulators of energy products the ability to reduce the total amount of caffeine in their products by as much as 50% without sacrificing consumers' expectations from such products.

The cross-over, clinical evaluation was designed to determine the relative bioavailability, pharmacokinetics and safety of PURENERGY™. This study was conducted by scientists from Miami Research Associates in Miami, Fla., led by principal investigator Dr. Diane R. Krieger.


The study compared the co-crystallized caffeine in PURENERGY™ with ordinary caffeine. The findings of the study showed:

- PURENERGY™ delivers almost 30% more caffeine into the blood than ordinary caffeine.

- The rate of caffeine absorption is significantly slower with PURENERGY™, by about 30% as compared to ordinary caffeine

- The half-life of caffeine from PURENERGY™ is extended significantly by about 25% over that of ordinary caffeine.

- At 4 hours, there was 45% more caffeine from PURENERGY™ compared to ordinary caffeine alone

- At 6 hours, there was 51% more caffeine from PURENERGY™ compared to ordinary caffeine alone.

- At 6 hours, subjects taking PURENERGY™ showed significantly less fatigue and greater concentration compared to baseline. Ordinary caffeine did not.

- At 6 hours, subjects taking PURENERGY™ showed improved energy, alertness and focus compared to baseline. Ordinary caffeine did not.

- PURENERGY™ showed no adverse effect.


Recently, caffeinated energy products have been coming under increased political and regulatory scrutiny because of the potential health risks associated with consuming large amounts of caffeine.

"The results of our clinical study of PURENERGY™ validate its suitability as an alternative to ordinary caffeine in energy drinks and other energy products, said Frank Jaksch, ChromaDex's co-founder and CEO. "PURENERGY™ balances the consumer's desire to feel the effects of caffeine with the pressure consumer product companies are under to reduce caffeine levels in finished products."

In conjunction with the clinical evaluation, ChromaDex commissioned Ipsos to conduct a national consumer survey of the caffeine consumption habits and attitudes of the American public. The survey reveals that although most Americans are committed to their daily caffeine habit, they would be interested in a product with less caffeine that delivers a sustained energy boost, but without the negative side effects associated with excessive caffeine consumption such as anxiety, jitters and increased heart rate.

ChromaDex's consumer survey found that 57 percent of American ages 18 to 54 reported consuming between two and five caffeinated beverages or products a day. According to the survey, 70 percent of Americans are either concerned about the potential health risks of using highly caffeinated products or have already stopped using these product altogether.

Seventy one percent of respondents age 18-34 reported that they were interested in a reduced caffeine energy beverage that provided the same benefits or feel without the negative side effects and the associated "crash" from ordinary caffeine.


Mr. Jaksch continued, "The consumer survey, which reveals that consumers are seeking a caffeine alternative that delivers less caffeine, but the same energy boost, validates the need for a safe, clinically studied ingredient like PURENERGY™."

The results of ChromaDex's clinical evaluation support those of an earlier animal study, which showed that PURENERGY™ has a longer half-life by comparison with caffeine alone.

In addition to being a caffeine alternative, PURENERGY™ has additional health benefits stemming from its co-crystal formulation with pTeroPure® pterostilbene, which has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic disorders. pTeroPure® was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.

PURENERGY™ and pTeroPure® are manufactured exclusively for ChromaDex by Laurus Labs, a leader in API (Active Pharmaceutical Ingredients) manufacturing.



About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and Niagen™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
ChromaDex Receives Strategic Investment From DSM Venturing - Oct 21, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Oct. 21, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global life sciences and material sciences company.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "It is with great pride and enthusiasm that we welcome DSM as a strategic investor in ChromaDex. We believe the investment demonstrates their confidence in the future of ChromaDex as well as our unique business model of acquiring and commercializing novel ingredient technologies."

Pieter Wolters, Managing Director DSM Venturing said, "We are pleased to invest in ChromaDex and thereby support Frank Jaksch and the entire ChromaDex team in the expansion of their business. We look forward to a mutually beneficial relationship."

The financial details of the investment were not disclosed.


About DSM – Bright Science. Brighter Living™:

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competencies in Life Sciences and Material Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of about €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
ChromaDex® Receives ISO/IEC 17025:2005 Certification - Oct 30, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Oct. 30, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that the ChromaDex analytics laboratory located in Boulder, Colorado has received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.

The ISO/IEC accreditation, which demonstrates technical competence for a defined testing scope and the operation of a laboratory quality management system, was granted by ACLASS, an ANSI-ASQ National Accreditation Board agency.

ISO/IEC 17025 is the international standard by which a laboratory's commitment to quality is evaluated. ChromaDex achieved this accreditation by demonstrating technical competence for the testing of dietary supplements. Competence requirements include testing performed using standard and/or non-standard methods and laboratory-developed methods. ISO 17025 not only considers the management and technical expertise, but also emphasizes continuous process improvement.

Commenting on the announcement, Frank Jaksch, ChromaDex Founder and CEO, states, "Receiving the ISO/IEC 17025 accreditation is a testament to our commitment for maintaining quality and excellence in our testing practices. The accreditation provides our customers with the utmost confidence that the accuracy of testing results produced by ChromaDex will carry a high degree of credibility and acceptance."

Mark Jost, Vice President of ChromaDex added, "ISO 17025 was identified as a key objective in our strategic planning process. Achieving the accreditation was a result of hard work and dedication by the entire ChromaDex laboratory staff."



About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
Universite Libre de Bruxelles +ChromaDex® To Collaborate on NIAGEN™ Nicotinamide Riboside Research; ChromaDex's NIAGEN™ is "the 1st +Only Commercially Available Nicotinamide Riboside" - Nov 5, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Nov. 5, 2013 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Universite Libre de Bruxelles (ULB), whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN™ nicotinamide riboside (NR).

Dr. Oberdan Leo, with the help of Drs. Fabienne Andris, Anthony Rongvaux and Frederic Van Gool at the Universite Libre de Bruxelles, identified the mammalian gene encoding for nicotinamide phosphoribosyl tranferase (Nampt), the rate limiting enzyme in the biosynthetic pathway linking nicotinamide (a major component of Vitamin B3) to NAD. The group led by Dr. Leo later demonstrated that this biosynthetic pathway plays an important role in lymphocyte development and in the regulation of innate immunity.

Dr. Leo commented, "The discovery that immune activation led to increased expression of Nampt led us to postulate intracellular NAD status may play an important role during an immune response. Exogenous NR has been shown to promote intracellular NAD accumulation and we are therefore thrilled by the possibility to explore, in collaboration with ChromaDex scientists, the effect of NR on the immune system in a series of preclinical models.

Commenting on the announcement, Frank Jaksch, ChromaDex Founder and CEO, states "We are pleased to partner with Dr. Leo and ULB, adding to the growing list of highly esteemed researchers and universities studying the important health benefits of nicotinamide riboside."

ChromaDex's NIAGEN™ has the potential to be a next generation niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

NIAGEN™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.



About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue their seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diets and improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About ULB:

Multicultural and international, that's the Universite libre de Bruxelles (ULB). A third of its students and researchers come from abroad, the ULB is like Brussels, a cosmopolitan center by excellence.

With thirteen faculties, schools and specialized centers, the ULB operates in all disciplines. Research and education are optimally matched. This leads to numerous collaborations and privileged partnerships with leading foreign universities.

The University distinguishes itself in a humanist approach to knowledge, through free, impartial research, and, in the words of Marie Curie, through its participation in fundamental research programmes. The university is proud to have won an array of awards that stand testament to its excellence, especially the four Nobel Prizes for science (including the 2013 Nobel Prize in Physics), 24 Francqui Prizes (out of 82), the highest honour in the sciences in Belgium, and 14 European Research Council grants.

ULB is incredibly active in finding business applications for the results of its research, with a specialist Technology Transfer Office (TTO) forming part of its Research Department. The TTO manages a portfolio of 162 patent families, 40 spin-offs, three incubators, and investment fund, and a biotechnology business park: Biopark Charleroi Brussels South.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
ChromaDex® Reports Results for the 3rd Quarter ´13 - Nov 21, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Nov. 21, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the third quarter ended September 28, 2013.

For the three months ended September 28, 2013, ChromaDex reported revenue of $2,718,207, as compared to $3,632,244 for the same period in 2012. The retail dietary supplement products segment did not have any sales for the three-month period ended September 28, 2013 as the Company sold its BluScience product line on March 28, 2013. For the same period in 2012, the retail dietary supplement products segment generated net sales of $1,642,334. The core standards, contract services and ingredients segment generated net sales of $2,355,458 for the three-month period ended September 28, 2013. This is an increase of 18%, compared to $1,989,910 for the same period in 2012. This increase was largely due to increased sales of proprietary ingredients and other bulk dietary supplement grade raw materials. The scientific and regulatory consulting segment, which is operated by the Company's subsidiary Spherix Consulting, Inc., generated net sales of $362,749 for the three-month period ended September 28, 2013. We did not have the scientific and regulatory consulting segment for the same period in 2012. The net loss attributable to common stockholders for the quarter ended September 28, 2013 was $1,250,263, or $0.01 per basic and diluted share, as compared to a net loss of $1,538,034, or $0.02 per basic and diluted share, for the same period in 2012. The net loss for the quarter ended September 28, 2013 is largely due to our share-based compensation expense. The non-cash, share-based compensation expense related to stock options and other share-based compensation for the third quarter of 2013 was $331,304. Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of decreasing the Company's net loss for the quarter ended September 28, 2013 to $918,959. As of September 28, 2013, cash, cash equivalents and marketable securities totaled approximately $1,087,424.

Subsequent to the quarter ended September 28, 2013, the Company received strategic equity financing from DSM Venturing and another strategic investor. The Company received an aggregate of $3,000,000 in gross proceeds, which will be used to further develop the Company's novel nutritional ingredients.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "The results of our clinical study of PURENERGY™ validate its suitability as an alternative to ordinary caffeine in energy drinks and other energy products. The announcement of the study has resulted in both media coverage highlighting the positive benefits of PURENERGY™ as well as substantial interest from companies with caffeinated products who have been searching for solutions to reduce caffeine."

Jaksch continued, "Since the commercial launch of NIAGEN™ in May 2013, the inbound inquiries we are receiving from both the research and business communities has been nothing short of astonishing. It was only after the launch of NIAGEN™ that we began to realize the magnitude of the existing wide-ranging interest in nicotinamide riboside as a precursor to NAD+. As we have previously stated, we still believe NIAGEN™ is perhaps the largest opportunity for creation of value for ChromaDex shareholders."


Recent and Q3 Company highlights include:

+ In May, the Company launched its novel, patented NIAGEN™, the first and only commercially available nicotinamide riboside, a precursor to NAD+. NIAGEN™ has the potential to become one of the most important B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

+ In July, the Company entered into a three-year supply agreement with Thorne Research, Inc. ("Thorne") pursuant to which Thorne shall purchase and market the Company's patented nicotinamide riboside, which is branded as NIAGEN™. Under the terms of the agreement, Thorne received marketing rights for NIAGEN™ for use in nutritional supplements exclusively for the direct to healthcare-practitioner channel in the United States and Canada, provided that Thorne purchases a minimum of $3.5 million of NIAGEN™ product over the next three years.

+ In September, the Company completed a cross-over clinical evaluation of its PURENERGY™ caffeine alternative – a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene. The study showed that PURENERGY™ delivers 30% more caffeine, stays in the blood stream longer and is absorbed more slowly than ordinary caffeine. Based on the clinical evaluation, PURENERGY™ provides formulators of energy products the ability to reduce the total amount of caffeine in their products by as much as 50% without sacrificing consumers' expectations from such products.

+ In October, the Company received a $2.5 million strategic equity investment from DSM Venturing, the corporate venture arm of Royal DSM, the global life sciences and material sciences company.

+ In October, the Company's laboratory located in Boulder, Colorado received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation. The ISO/IEC accreditation, which demonstrates technical competence for a defined testing scope and the operation of a laboratory quality management system, was granted by ACLASS, an ANSI-ASQ National Accreditation Board agency.

+ In November, the Company entered into a material transfer agreement with Universite Libre de Bruxelles ("ULB"), whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN™ nicotinamide riboside. In July, the Company announced a similar MTA with the Scripps Research Institute.


Separately, on November 21, 2013, in a filing on Form 8-K with the SEC, the Company disclosed that as a result of a change in accounting of the previous sale of its BluScience assets to NeutriSci International, Inc. ("NS") from the Cost Method to the Equity Method, its financial statements for the three month period and six month period ending March 30, 2013 and June 29, 2013, respectively, contained in the Company's Quarterly Reports on Form 10-Q (" Quarterly Reports") as filed with the SEC should no longer be relied upon because of certain non-cash items in the Quarterly Reports and that those financial statements would be restated to make the necessary accounting adjustments.

The value of the equity and the senior secured convertible note that the Company received from NS as part of the purchase price were originally accounted for at the face value of the assets for recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NS equity securities and the ultimate collectability of the notes received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company's cost basis in the net assets sold has been recovered. The Company originally accounted for its investment in NS under the Cost Method where it has now be determined that the Equity Method should have been used. The Company expects all amendments and restatements to the Financial Statements affected to be non-cash in nature. The Company will restate the Financial Statements to correct the errors noted above and file amendments to the previous periods Quarterly Reports with the SEC as soon as practicable.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com "
ChromaDex® Updates Research Activity Agreements For Its NIAGEN™, "ChromaDex's NIAGEN™ is the 1st +Only Commercially Available Nicotinamide Riboside Nicotinamide Riboside" - Nov 22, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Nov. 22, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced an update on recent material transfer agreement activity with significant universities and research institutes for its NIAGEN™ nicotinamide riboside (NR).

The Company is pleased to report that it has received an unprecedented :eek: :eek: number of inquiries from universities and research institutes from around the world who have expressed interest in entering into agreements for ChromaDex to provide quantities of its NIAGEN™ nicotinamide riboside for planned research studies. Studies conducted by researchers will add to the growing amount of data showing many of the important health benefits of nicotinamide riboside, and portends possible pharmaceutical uses for NIAGEN™.


Commenting on the announcement, Frank Jaksch, ChromaDex Founder and CEO, states "It was only :eek: after we launched NIAGEN™ that we began to fully understand the existing widespread interest within the research community regarding nicotinamide riboside as a precursor to NAD+. We are pleased to have signed agreements with such esteemed institutions as MIT, Universite Libre de Bruxelles and The Scripps Research Institute and hope to continue to add to the growing list of highly renowned researchers and universities studying the important health benefits of nicotinamide riboside."

Most recently, ChromaDex entered into a material transfer agreement (MTA) with Massachusetts Institute of Technology ("MIT") whereby ChromaDex will provide MIT with quantities of its NIAGEN™ nicotinamide riboside for research purposes.

Dr. Leonard Guarente, Novartis Professor of Biology at MIT, has been studying the relationship between sirtuins, which are novel nicotinamide adenine dinucleotide, or NAD+ dependent protein deacetylases, and aging and diseases of aging. His studies have shown that sirtuins help mediate the health-promoting effects of a diet of calorie restriction. Recent studies by his and other labs have shown that aging or diseases can reduce the levels of NAD+ or alter the balance between NAD+ and NADH, an electrically neutral form of the molecule. Extensive data shows that increasing levels of the sirtuin SIRT1 in the brain protects against several neurodegenerative diseases in transgenic rodent models, but that protection is incomplete. In future studies, Guarente will address whether increasing NAD+ levels via nicotinamide riboside (NR) supplementation, by itself or in combination with increasing SIRT1 levels, confers additional protection.

Earlier this month, ChromaDex entered into a material transfer agreement with Universite Libre de Bruxelles ("ULB"), whereby the company will provide ULB with quantities of its recently launched NIAGEN™ nicotinamide riboside.

Dr. Oberdan Leo, with the collaboration of Drs. Fabienne Andris, Anthony Rongvaux and Frederic Van Gool at the Universite Libre de Bruxelles, identified the mammalian gene encoding for nicotinamide phosphoribosyl tranferase (Nampt), the rate limiting enzyme in the biosynthetic pathway linking nicotinamide (a major component of Vitamin B3) to NAD. The group led by Dr. Leo later demonstrated that this biosynthetic pathway plays an important role in lymphocyte development and in the regulation of innate immunity.

Dr. Leo commented, "The discovery that immune activation led to increased expression of Nampt led us to postulate intracellular NAD status may play an important role during an immune response. Exogenous NR has been shown to promote intracellular NAD accumulation and we are therefore thrilled by the possibility to explore, in collaboration with ChromaDex scientists, the effect of NR on the immune system in a series of preclinical models."

Lastly, in July 2013, the Company entered into an agreement with The Scripps Research Institute ("TSRI") also to provide TSRI with quantities of NIAGEN™ nicotinamide riboside for research purposes. TSRI researchers have been studying the relationship between dysfunction of mitochondria, the energy-producing parts of the cell, and various life-threatening diseases. More specifically, the studies have focused on whether disease-affected cells change the balance between nicotinamide adenine dinucleotide, or NAD+, which has a positive charge, and NADH, an electrically neutral form of the molecule.

TSRI research has shown that therapeutic normalization of the NAD+/NADH balance can prevent the disease progression. The results translate into a new therapeutic strategy: enhancement of the NAD+/NADH balance through treatment with NAD+ precursors, such as nicotinamide riboside.

ChromaDex's NIAGEN™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight loss, energy drinks, sports nutrition, meal replacements, infant formula, and the food and beverage industry.


NIAGEN™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.



About Nicotinamide Riboside(NR):

Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue their seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diets and improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and NIAGEN™, its recently launched branding nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com. "
ChromaDex® to Present @Sixth Annual LD Micro Conference, on December 4, 2013 - Dec 2, 2013
http://app.quotemedia.com/quotetools/newsStoryPopup.go?story…

"IRVINE, Calif., Dec. 2, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it is scheduled to present at the 6th Annual LD Micro Conference on Wednesday, December 4, 2013, at 10:00 AM PST / 1:00 PM EST.

The three-day event will be held December 3 – 5 at the Luxe Sunset Bel Air Hotel in Los Angeles. More than 225 companies are expected to present. Frank Jaksch, Jr., CEO and co-founder of ChromaDex, will present on behalf of the Company. Investors interested in having a one-on-one meeting with Mr. Jaksch should contact Robert Prag at the The Del Mar Consulting Group, Inc. at the contact information provided below.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
International Stevia Council +ChromaDex Enter Into Agreement, for Reference Benchmark Standard; ChromaDex "Tapped to Provide ISC with Reference Benchmark Standard :eek: , in Proficiency Testing Program for Stevia Leaf Extract" - Dec 18, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
www.internationalsteviacouncil.org/index.php?id=4

"BRUSSELS and IRVINE, Calif., Dec. 18, 2013 /PRNewswire/ -- The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.

"The aim of the new Reference Benchmark Standard is twofold," explained Larry Fernandes, president of the ISC. "We want to ensure we continue improving our testing capabilities in the PTP by having all participants use the same Reference Benchmark Standard to remove the potential differences attributable to using multiple reference standards. Introducing a common reference baseline across all participants will provide more focused and better guidance as to differences in methods and laboratory practices in the PTP from a statistical point of view."

"We are pleased to be working with the International Stevia Council," said Frank L. Jaksch Jr., ChromaDex's founder and chief executive officer. "The council's selection of ChromaDex to provide such important industry benchmarking of methods and analytical standards in accordance with international quality standards is a testament to our commitment to quality and our proven experience."

The PTP was launched by the ISC in 2011. In addition to members of the ISC, participants in the program also include companies, laboratories and research organizations. For more information about the program, please visit http://www.internationalsteviacouncil.org/index.php?id=4.


About the International Stevia Council:

The International Stevia Council is a global trade association representing the interests of companies that process, manufacture and/or market stevia sweetener products. The International Stevia Council is a 501(c)(6) not-for-profit organization incorporated under the law of the State of Delaware in the United States. The council was created in July 2010 by 11 founding members. The council is managed by its global office in Brussels, Belgium.


About Stevia:

Stevia is a plant of the Asteraceae (sunflower) family whose leaves have been used as a sweetener in South America for hundreds of years. Extracts of the stevia leaf have been available as food additives (sweeteners) and/or dietary supplements in many countries around the world.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched, branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.


Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


International Stevia Council Contact:

Maria Teresa Scardigli, +32 2 761 16 51, media@internationalsteviacouncil.org.


ChromaDex Investor Contact:

The Del Mar Consulting Group, Inc., Robert B. Prag, president, 858-794-9500, bprag@delmarconsulting.com

or

Alex Partners, LLC, Scott Wilfong, president, 425-242-0891, scott@alexpartnersllc.com


ChromaDex Company Contact:

Laura Carney, executive assistant,
949-419-0288,laurac@chromadex.com
SOURCE ChromaDex "
ChromaDex® Appoints Former Nestle Executive :eek: to Its Board of Directors - Jan 3, 2013
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., Jan. 3, 2014 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.

Allen, age 64, has extensive experience in negotiating merger and acquisition deals and coordinating related due diligence. He has many years of experience handling both in and out-licensing agreements with technology providers and branded companies.

Allen retired from Nestle in December 2009 after a 30-year career in sales, marketing and general management. In 2002, he joined the Mergers and Acquisitions group of Nestle. He was heavily involved in their venture capital investments (Nestle has over $800 million invested in a variety of venture funds) as well as out licensing technologies.

He is currently non-executive Vice-Chairman of 6 Pacific Group (http://www.6pacificgroup.com), a Los Angeles based boutique advisory and investment firm, which assists food and beverage companies with capital formation, acquisitions and divestitures. Recently the firm represented New Chapter in the sale to Procter & Gamble -- one of the most significant acquisitions in the supplement business in recent years.


Allen co-founded and is a member of the Screening Committee of Nutrition Capital Network (http://www.nutritioncapital.com), a business that brings together entrepreneurs and investors in the nutrition and food industries. The major global food and beverage companies (e.g. Coca-Cola, Unilever, General Mills, PepsiCo, Campbell's, Amway, Hershey's and Nestle) are cornerstone investors in Nutrition Capital Network and attend the three meetings each year where exciting new investment and partnering opportunities are presented.

Allen is also the Managing Partner of California Agricultural Orchards LLC, which owns almond properties in the Central Valley of California and is President of the Board of the North American Foundation for the University of Leeds (http://www.leeds.ac.uk) where he obtained a B.Sc. with Honors.


Commenting on the appointment, Allen stated, "I have known of and followed ChromaDex for years, and am proud to join its Board of Directors. The Company and its management have an excellent reputation within the nutritional supplement industry and the accomplishments in their ingredient technologies business, in such a short time frame, is nothing short of outstanding. I feel my experience, skill sets and industry contacts are very well suited for this appointment. I look forward working with Frank Jaksch and entire ChromaDex team."

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "It is with great pride and enthusiasm that I welcome Steve as a ChromaDex director. His tremendous insight and experience in the nutritional industry will be a great asset to both our Board and management team."

ChromaDex also announced the resignation of Curtis Lockshin from its Board of Directors. The total number of board members remains at nine, of which the majority are independent.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.


Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.


ChromaDex Investor Contact:

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC
Scott Wilfong, President
425-242-0891
Scott@alexpartnersllc.com

ChromaDex Contact:

Laura Kelly, Executive Assistant
949-419-0288
laurak@chromadex.com

SOURCE ChromaDex "
:eek:

ChromaDex® Announces $62.000.000 Ingredient Agreement with Network Marketing Company 5LINX®, "one of the largest and fastest-growing direct marketing companies in the world"; Four Year Deal is for ChromaDex's NIAGEN™ Nicotinamide Riboside +PURENERGY™ - Jan 6, 2014
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://hms.harvard.edu/news/genetics/new-reversible-cause-ag…
www.cell.com/abstract/S0092-8674%2813%2901521-3
http://weill.cornell.edu/news/releases/wcmc/wcmc_2012/06_14_…
www.inc.com/profile/5linx-enterprises

"IRVINE, Calif., Jan. 6, 2014 /PRNewswire/ -- ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX®, one of the largest and fastest-growing direct marketing companies in the world.

5LINX® has been granted marketing rights for ChromaDex's recently launched patented NIAGEN™ Nicotinamide Riboside (NR) for use in dietary supplements exclusively in the network marketing sales channel in the United States, Canada and Philippines. Under the terms of the agreement, 5LINX® must purchase from ChromaDex $2.1 million of NIAGEN™ in 2014, and an aggregate of $46 million of NIAGEN™ from 2015 through 2017. NIAGEN™ is the first and only commercially available brand of NR, which is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism.


5LINX® has also been granted marketing rights for ChromaDex's recently launched patented PURENERGY™ for use in dietary supplements, with select exclusively in the network marketing sales channel in the U.S., Canada and Philippines. Under the exclusive network marketing channel agreement, 5LINX® must purchase from ChromaDex $520,000 of PURENERGY™ in 2014 and an aggregate of $14 million of PURENERGY™ from 2015 through 2017. ChromaDex's PURENERGY™ caffeine alternative is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene, a potent anti-oxidant found in blueberries. The first human study of PURENERGY™ demonstrated PURENERGY™ delivers 30 percent more caffeine, stays in the blood stream longer, and is absorbed more slowly than ordinary caffeine. With PURENERGY™, formulators of energy products may have the ability to reduce the total amount of caffeine in their products by as much as 50% without sacrificing consumers' expectations from such products.

"The health and wellness stories behind NIAGEN™ and PURENERGY™ make each ingredient ideal candidates for us to launch a suite of wellness products that will accelerate the growth in our new wellness segment," says Craig Jerabeck, CEO of 5LINX®. "We view this deal as an incredible opportunity for 5LINX® to be among the first to offer dietary supplements featuring NIAGEN™ Nicotinamide Riboside and PURENERGY™."

Frank Jaksch, ChromaDex Founder and CEO, states "We believe the network marketing channel is ideal for the early development and adoption of NIAGEN™ and PURENEGY™-based health and wellness products. We are impressed with the historical success that Craig and his 5LINX® management team have demonstrated in building a long-term sustainable sales and marketing network, and becoming recognized as one of the largest and fastest-growing direct marketing companies in the world."


About NIAGEN™ Nicotinamide Riboside (NR):

ChromaDex's NIAGEN™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products.

NIAGEN™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased anti-aging, fatty acid oxidation, mitochondrial activity, resistance to negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and blocking muscle degeneration.

Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries in providing evidence for unique properties of NR in neuroprotection,sirtuin activation, protection against weight gain on high fat diet and improvement of blood glucose and insulin sensitivity.

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging was published in December 2013 in CELL regarding the effect that increased levels of NAD+ has on the aging process.

Findings from another recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About PURENERGY™:

ChromaDex's PURENERGY™ is a novel, patented next-generation functional caffeine alternative derived from the technology-driven fusion of caffeine and ChromaDex's patented pTeroPure® pterostilbene. The first human study of PURENERGY™ demonstrated PURENERGY™ delivers 30% more caffeine, stays in the blood stream longer, and is absorbed more slowly than ordinary caffeine. With PURENERGY™, formulators of energy products may have the ability to reduce the total amount of caffeine in their products by as much as 50% without sacrificing consumers' expectations from such products. Clinical studies show the ingredient provides a rapid and sustained energy boost for at least 6 hours and the potential for a more moderated and gradual finish, preventing the "crash" experienced with caffeine products.

In addition to being a caffeine alternative, PURENERGY™ has additional health benefits stemming from its co-crystal formulation with pTeroPure® pterostilbene, which has shown great promise for supporting heart health, cognitive function, anti-aging, weight loss and other metabolic disorders. pTeroPure® was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan.


About 5LINX®:

5LINX® offers a unique work from home business opportunity based on essential products and services people use every day. 5LINX® distributes its products and services through a network of dedicated independent marketing representatives. 5LINX® has earned the distinction as being recognized by Inc. Magazine as one of the 5,000 fastest-growing privately-held companies in the country for the last eight years. In 2012 and 2013, 5LINX® was named to the Global 100 List compiled by Direct Selling News, the premier direct sales industry magazine, making 5LINX® one of the 100 largest direct sales companies in the world.


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 46.244.993 von Popeye82 am 17.01.14 05:56:22
ChromaDex CEO Frank Jaksch to Be Interviewed Today, on Clear Channel Business Talk Radio DFW 1190AM - Jan 6, 2014
www.yorbamedia.com/images/stories/audio/TN010614SEG4.mp3
www.stockhouse.com/news/press-releases/2014/01/06/chromadex-…
ChromaDex CEO to Present @the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd @8:30 am EST - Jan 17, 2014
http://app.quotemedia.com/quotetools/newsStoryPopup.go?story…
http://noble.mediasite.com/mediasite/Play/2ea55381d9a443f880…

"IRVINE, Calif., Jan. 17, 2014 /PRNewswire/ -- ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.

Jaksch will also be available during the conference for one-on-one meetings. To schedule a meeting, please contact your Noble Financial representative or contact Bob Prag at The Del Mar Consulting Group, Inc. at (858) 361-1786 or bprag@delmarconsulting.com.

At the time of the presentation, a live audio and high-definition video webcast of the ChromaDex presentation and a copy of the presentation materials will be available through the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/TEN/2014.htm or at http://noble.mediasite.com/mediasite/Play/2ea55381d9a443f880…

Those wishing to listen are encouraged to register at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download is available from the presentation link) to participate. The webcast and presentation will also be archived on www.chromadex.com for 90 days following the event.


About Noble Financial:

Noble Financial Capital Markets was established in 1984; 2014 marks its 30th Anniversary. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 - 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com


About ChromaDex®:

ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin; PURENERGY™, a caffeine-pTeroPure co-crystal; pTeroPure® pterostilbene; and, ProC3G™, a natural black rice containing cyanidin-3-glucoside. To learn more about ChromaDex, visit www.chromadex.com. "
7:25 aufwärts:

ChromaDex Signs Material Transfer Agreement, With Leading Dutch University for NIAGEN™ Research; NIAGEN™ is the 1st +only commercially available Nicotinamide Riboside - Mar 12, 2014
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., March 12, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN™ nicotinamide riboside (NR) ingredient.

NIAGEN™ is the first and only commercially available form of NR, a naturally-occurring vitamin B3 derivative. NR is naturally found in the whey fraction of milk and beer, and it is a potent precursor to NAD+ in the cell. NAD+ is essential to healthy cell metabolism.

Dr. Michael Jaehme, a researcher at the GBB, will investigate the uptake of NR into cells and how it is converted in the biologically active nucleotides NMN and NAD+. In addition to co-crystallization experiments to study the molecular basis of NR protein interactions, he aims to determine binding constants to quantify the efficiency of cellular NR utilization. Examining these interactions at the molecular level can yield valuable insight into how NR exerts its biological effects.

Dr. Jaehme commented, "Transport as the first step of NR utilization is poorly understood in humans, as well as in bacteria. A pathogenic microorganism that is dependent on the uptake of NR to acquire NAD+ is Haemophilus influenzae. Although mammalian NR transport systems have not been identified, uptake systems homologous to the bacterial ones are not present. That shows the potential of prokaryotc NR uptake and utilization pathways as drug targets. We are glad to have the possibility to investigate these mechanisms with the help of ChromaDex."

"The health benefits of nicotinamide riboside are supported by a large body of scientific evidence," said Frank Jaksch, Jr., founder and CEO of ChromaDex. "Specifically, NR is a potent precursor to NAD+, an essential element of all living cells that is vital for the health of mitochondria, the energy powerhouses of the cell. In fact, a recently published study by Dr. David Sinclair of Harvard Medical School affirmed the role of NAD+ boosters in supporting healthy aging. This partnership with GBB is the latest in a number of important collaborations with leading research institutes to advance scientific understanding of NR and its mechanism of action."

NAD+ is an essential element of all living cells that plays a key role in cellular metabolism and energy production. NAD+ is vital for the health of mitochondria, the powerhouses of the cell that convert sugars, fats and proteins into energy for use by the body. As organisms age, levels of NAD+ drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health concerns. Low NAD+ levels limit the activity of a group of enzymes called sirtuins that are believed to play a key role in longevity. NAD+ levels can also be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+ levels, NR can increase mitochondrial health and induce the creation of new mitochondria, thus supporting cell performance, endurance, metabolism, neuroprotection, healthy aging and cardiovascular health.


NIAGEN™ has the potential to become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University.


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle :eek: :eek: Molecule" or "Hidden :eek: Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3).

Published research has shown that NR is perhaps the most effective NAD+ booster, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouse of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include: increasing mitochondrial health, increasing muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on high fat diet, protection against oxidative stress, improvement of blood glucose and insulin sensitivity.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging was published in December 2013 in CELL demonstrated that mitochondrial dysfunction (a hallmark of ageing) in ageing mice is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial communication. They further show that a reduction in NAD+ levels is responsible for this disruption. Excitingly, they also show that this mitochondrial dysfunction is readily reversible by administration of a NAD+ precursor. The authors show that "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse."


About Groningen Biomolecular Sciences and Biotechnology Institute (GBB):

The Groningen Biomolecular Sciences and Biotechnology Institute (GBB) is a research institute at the Faculty of Mathematics and Natural Sciences, University of Groningen. GBB also acts as a KNAW-accredited Dutch research school that since 2010 is embedded within the Graduate School of Science.

GBB has the ambition to perform research of the highest standard in the field of biomolecular sciences, studying microbial processes and cells. With strong roots in chemistry, biophysics, molecular biology, and genetics, GBB has become a well-recognized research institute in biomolecular science with a focus on genetic and metabolic processes and structure-function studies of the biomolecules involved. Recently, GBB has seen a remarkable growth in microbiological sciences, stimulated by strong teams incorporating modern approaches in genomics, single cell- and single molecule analyses, high-resolution microscopy, and advanced cell engineering. In view of the emerging societal and industrial need to develop sustainable bio-based processes, and the undisputed and important role that microbial processes play in this field, GBB strives to further concentrate its research profile in two focal areas: Molecular Mechanisms of Bioprocesses and Physiology and Systems Biology.


About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
Thorne Research Introduces a New Product, NiaCel™, Featuring NIAGEN™, To Support Healthy Aging - Apr 2, 2014
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., April 2, 2014 /PRNewswire/ -- Thorne Research today announced the launch of NiaCel™, an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel™ is one of the first commercially available products to feature the ingredient NIAGEN™ from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.

ChromaDex developed its breakthrough patent-protected ingredient NIAGEN™ as the first and only commercially available brand of nicotinamide riboside (NR). NR, the active ingredient in NiaCel™, boosts levels of NAD+ in cells and tissue. Studies have demonstrated that increasing the levels of NAD+ can support healthy aging by stimulating mitochondrial energy production, as well as by activating sirtuin function.


Paul Jacobson, the CEO of Thorne Research, stated, "We are very excited to offer NIAGEN nicotinamide riboside to our practitioner network through this new, exclusive product launch. NiaCel provides practitioners with a powerful new solution to promote healthy aging in patients. NIAGEN is one of the most innovative new ingredients developed in the past decade. We are thrilled to partner together with ChromaDex and our practitioner-customer base to enhance patient health with the introduction of NiaCel."

Frank Jaksch, ChromaDex founder and CEO, stated, "NiaCel is truly a groundbreaking product. We are pleased to have Thorne Research feature NIAGEN, our branded nicotinamide riboside, in such a prominent product launch."


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush vitamin B3 (Niacin) derivative.

Published research has shown that NR is perhaps the most effective NAD+ booster, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouse of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule scientists will see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include increasing mitochondrial health, increasing muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on a high-fat diet, protection against oxidative stress, improvement of blood glucose, and insulin sensitivity to maintain blood sugar levels within the normal range.

Findings from a recent study by Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed that mice on a high-fat diet that were fed NR gained 60-percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging, published in December 2013 in CELL, demonstrated that mitochondrial dysfunction (a hallmark of aging) in aging mice is due to a disruption in sirtuin1-dependent nuclear-mitochondrial communication. They further showed that a reduction in NAD+ levels is responsible for this disruption. They also showed this mitochondrial dysfunction was readily reversible by administration of a NAD+ precursor. The authors found that "one week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse."


About ChromaDex Corp.:

ChromaDex is an innovative natural products company that discovers, acquires, develops, and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.


About Thorne Research, Inc.:

Since 1984, Thorne Research, with more than 400 nutritional supplement products, has set the standard for exceptional quality manufacturing and formulation of pure, highly absorbable nutritional supplements using advanced technology. Thorne Research is recognized as a global leader and provider of nutritional supplements and education to licensed health-care practitioners. With locations in Sandpoint, Idaho, and New York City, Thorne Research operates a state-of-the-art manufacturing facility and employs more than 260 people. Further information on Thorne Research is available at www.thorne.com.


Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


ChromaDex Company Contact:

Laura Carney, Executive Assistant
949-419-0288
laurac@chromadex.com

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corp. "
ChromaDex Signs Collaboration Research Agreement, with Brazilian Research Institute - Apr 7, 2014
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., April 7, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with Brazilian Biosciences National Laboratory (LNBio) to evaluate ChromaDex's natural product libraries.

ChromaDex and LNBio are establishing a collaboration to screen natural product libraries against certain molecular targets and phenotypic assays with the intent of identifying high value, possibly patentable natural products for specific therapeutic indications.
Under the terms of the agreement, ChromaDex will be responsible for providing the natural product libraries for screening, as well as the natural product chemistry expertise to continue the development of any identified candidates into commercial opportunities. LNBio will screen the natural product libraries provided by ChromaDex, as well as continue performing assays in enzymes, cells and organisms related to the discovery of chemical entities that are the object of this collaboration.


"ChromaDex's expertise in developing natural product libraries, and natural products chemistry, as well as its success in commercializing novel, branded ingredients, makes ChromaDex the ideal partner for this type of high throughput screening collaboration," said Kleber Gomes Franchini, Director of LNBio. "If successful, this collaboration could lead to rapid commercialization of novel natural products for food, beverage, cosmetic or pharmaceutical applications."

"The ChromaDex catalog offers thousands of very unique phytochemical compounds primarily isolated from botanicals," said Frank Jaksch, Jr., founder and CEO of ChromaDex. "We are very excited to start this collaboration with LNBio, as this program will allow ChromaDex to extract value from the natural products library we have been developing over the past 15 years"


About LNBio:

The Brazilian Biosciences National Laboratory (LNBio) is part of the Brazilian Center for Research in Energy and Materials (CNPEM), a private research and development institution (R&D) funded mainly by the Brazilian Ministry of Science, Technology, and Innovation (MCTI). LNBio is dedicated to research and innovation in biotechnology and drug discovery and development. The Laboratory activities are organized into four axes: Open Facilities; Innovation Core; Internal Research; Training and Education. This organizational strategy was designed to encourage the sharing of infrastructure and skills with the academic and industrial sectors. LNBio brings together competences, cutting edge equipment and a team of world-class researchers focused on conducting multidisciplinary studies in the areas of structural biology, proteomics, genomics, metabolomics, high-throughput screening (HTS) and high-content screening (HCS), development of genetically modified organisms (GMO), among others.


About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
ChromaDex Signs Material Transfer Agreement With University of Copenhagen, for NIAGEN™ Nicotinamide Riboside Research - Apr 15, 2014
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…

"IRVINE, Calif., April 15th, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen, Denmark. ChromaDex will provide the University with quantities of its patented NIAGENTM nicotinamide riboside (NR) ingredient for use in research.

ChromaDex's NIAGEN™ is the first and only commercially available form of NR, a naturally-occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has also been recognized as an extracellular signaling molecule involved in cell-to-cell communication. NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy.

Dr. Jonas Thue Treebak, Assistant Professor of the Novo Nordisk Foundation Center for Basic Metabolic Research, will investigate the role of NAD+ salvage systems for maintaining mitochondrial function and insulin sensitivity. Specifically, various in vitro and in vivo experimental models with defects in these systems will be treated with NR to determine the ability of this compound to restore a healthy phenotype. This project is made possible in part by a recent prestigious grant obtained by Dr. Treebak from the Novo Nordisk Foundation.

Dr. Treebak commented, "The ability to maintain mitochondrial function in insulin sensitive tissues in the body appears to be tightly linked to development of insulin resistance and Type 2 Diabetes. With generous support from the Novo Nordisk Foundation and ChromaDex, we can engage in this important and exciting research area to answer fundamental questions regarding the role of NAD+ metabolism in these diseases; hopefully for the health benefit of millions of people world-wide."

"We are excited to support Dr. Treebak's innovative research," said Frank Jaksch, Jr., founder and CEO of ChromaDex. "Rapidly accumulating scientific evidence supports a wide range of potential health benefits provided by NR supplementation. We are pleased to add the Novo Nordisk Foundation Center for Basic Metabolic Research to the ever-growing list of our esteemed academic and research partners studying NR."


About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3).

Published research has shown that NR is perhaps the most effective NAD+ booster, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouse of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include: increasing mitochondrial health, increasing muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on high fat diet, protection against oxidative stress, improvement of blood glucose and insulin sensitivity. In recent years, NAD+ has also been recognized as an extracellular signaling molecule involved in cell-to-cell communication.

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging was published in December 2013 in CELL demonstrated that mitochondrial dysfunction (a hallmark of ageing) in ageing mice is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial communication. They further show that a reduction in NAD+ levels is responsible for this disruption. Excitingly, they also show that this mitochondrial dysfunction is readily reversible by administration of a NAD+ precursor. The authors show that "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse."

Separately, findings from a 2012 study conducted by researchers at Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne , Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."


About the University of Copenhagen:

With over 38,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark. The purpose of the University – to quote the University Statute – is to "conduct research and provide further education to the highest academic level". Approximately one hundred different institutes, departments, laboratories, centers, museums, etc., form the core of the University, where professors, lecturers and other academic staff, as well as most of the technical and administrative personnel, carry out their daily work, and where teaching takes place.

The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center established in 2010 at the University of Copenhagen. It is partially funded by an unconditional donation from the Novo Nordisk Foundation. The center aims to be a globally leading center for metabolic research, and researchers at the Center generate basic knowledge about human metabolism as a basis for new methods of diagnosing, preventing and treating type 2 diabetes and obesity.


About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com. "
Antwort auf Beitrag Nr.: 43.086.079 von montamero am 25.04.12 13:31:37
Dr. Phillip Frost Leads Investment in Drone Aviation Holding(OTCQB: DRNE), +Is Appointed Chairman of Its Strategic Advisory Board - Aug 28, 2014
http://content.stockpr.com/_news/droneaviationcorp/2014-08-2…

"JACKSONVILLE, FL--(Marketwired - Aug 28, 2014) - Drone Aviation Holding Corp. (OTCQB: DRNE), a developer of specialized tethered drones and lighter-than-air aerostats, today announced that it formed a Strategic Advisory Board that will be headed by Dr. Phillip Frost and that it has accepted subscriptions in a private placement of securities of the Company. Joining Dr. Frost on the newly formed Board is Mr. Steve Rubin.

The Company accepted subscriptions for an aggregate of 1,100,333 shares (the "Shares") of the Company's Series F Convertible Preferred Stock, each of which is convertible into one (1) share of Common Stock of the Company, in a private placement of up to $1,500,000 of its securities to certain accredited investors at a purchase price of $0.75 per Share for an aggregate purchase price of $825,250. Dr. Frost led the investment in the private placement.

"Dr. Frost has a distinguished entrepreneurial track record of success throughout the business community as well as the public marketplace and we are honored to have him Chair our Strategic Advisory Board and as an investor in our Company," stated Felicia Hess, CEO of Drone Aviation Holding Corp. "His extensive government and military relationships during his 13 year tenure as a Director of Northrop Grumman, combined with his capital market expertise, make him an ideal Chairman to lead our newly formed Strategic Advisory Board."

Phillip Frost, M.D. currently serves as the Chairman of the Board and Chief Executive Officer of OPKO Health, Inc., a specialty pharmaceutical company. Additionally, Dr. Frost serves as Chairman of the Board of Directors of TEVA Pharmaceuticals, Ltd., Ladenburg Thalmann Financial Services, Inc. and Prolor Biotech, Inc. and also serves as a Director of Castle Brands, Inc.

Previously, Dr. Frost served as a Director for Northrop Grumman Corp., a global defense company that generates approximately $25 billion in annual revenue and provides technologically advanced, innovative products, services and solutions in systems integration, defense electronics, information technology, advanced aircraft, shipbuilding and space technology. With more than 120,000 employees and operations in all 50 states and 25 countries, Northrop Grumman supplies products and services to the U.S. and international military, government and commercial sectors.

He also previously served as the Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation until its sale to TEVA and Director of Continucare Corp. prior to its sale to Metropolitan Health Networks Inc. Dr. Frost also served on the Board of Directors of IVAX Diagnostic (Chairman) and the American Stock Exchange (Co-Vice Chairman).

Mr. Rubin has served as Executive Vice President and as a director of OPKO Health, Inc. since February 2007. He has extensive experience as a practicing lawyer, general counsel, and board member to multiple public companies.


About Drone Aviation Holding Corp.

Drone Aviation Holding Corp. (OTCQB: DRNE) provides critical aerial and land based surveillance and communications solutions to government and commercial customers. Utilizing a unique tethering capability, Drone systems operate in the National Airspace within FAA guidelines for safe operations. Drone systems are designed and developed in-house utilizing proprietary technologies and processes that result in compact, rapidly deployable aerostat solutions and mast based systems that have been proven to fulfill critical requirements by the military and law enforcement in the U.S. and to our allies around the world. For more information about Drone Aviation Holding Corp., please visit www.DroneAviationCorp.com, or view our reports and filings with the Securities and Exchange Commission on http://www.sec.gov. "
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://tailwindsresearch.com/2018/02/cdxc-seller-revealed-in…
"Chromadex Seller Revealed in SEC Filings
Ever since Mark Zuckerberg's Iconiq Capital invested, shares of CDXC started a surprising slide. This week the source of the pressure was revealed in filings that a former backer was liquidating his position. This has simply created a buying opportunity, especially since they pre-announced revenues well ahead of WS estimates........................................"
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://www.washington.edu/
http://www.cam.ac.uk/
https://clinicaltrials.gov/
http://journals.plos.org/plosone/article?id=10.1371/journal.…
http://aboutnad.com/
"Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure

IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that two new collaborative human clinical studies on NIAGEN® Nicotinamide Riboside (NR) have registered and are now underway at the University of Cambridge and the University of Washington.

ChromaDex Co-Founder and CEO, Frank Jaksch, commented, “With nearly 140 collaborative agreements in place, we continue to shape the landscape of NR and NAD research, ensuring that each study helps to quantify the value of NIAGEN® and its role in human health.”

The University of Cambridge research team will study 15 patients with mitochondrial disease to determine whether NIAGEN® induces mitochondrial biogenesis and affects mitochondrial function in patients with mitochondrial myopathy. This trial is expected to complete in late Spring, 2019.

The second study, at the University of Washington, will include 30 patients with clinically stable, systolic heart failure. The research team primarily aims to assess the safety and tolerability of NIAGEN® in this high-risk population. The team will also collect exploratory data on the effects of NIAGEN® on cardiovascular functional capacity in these patients. Registration of the study quickly follows publication of their last human clinical trial which published early December, 2017. This latest study is currently expected to complete at the end of June, 2018.

“By offering clinical study products at no cost for double-blind, placebo controlled independent research, we are enabling the next phase of research in humans, and in at-risk populations where NIAGEN® has the potential to improve quality of life. Most of these major human investigations are funded by national research funding bodies and other research organizations unrelated to ChromaDex which attests to the promising future of NIAGEN®,” Robert N. Fried, President and Chief Operating Officer of ChromaDex shared.

ChromaDex has enabled global NIAGEN® research in a diverse set of health-related fields by providing their safety-verified, NIAGEN® at no cost to independent investigators who are leading nearly 140 programs in 34 different areas of health research including brain health, Alzheimer’s and cognitive support, heart health, and inflammation. To date there are 3 published clinical trials of NIAGEN® and NIAGEN® is being studied in at least 13 of the 16 human trials currently registered on clinicaltrials.gov.

For more information on ChromaDex, visit www.chromadex.com.

About NAD
NAD activates cellular metabolism and energy production within the cell’s “power stations,” the mitochondria. Our mitochondria are constantly working to convert the food into the energy necessary to power all bodily systems as well as help us stay healthy enough to ward off illness. The challenge is that both NAD levels and mitochondrial functions decline as we age. This reduction in NAD is believed by scientists to be linked to a wide variety of age-related diseases and conditions. For more information on NAD, visit AboutNAD.com

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:
This release contains forward-looking statements relating to ChromaDex and ChromaDex’s business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the clinical studies and potential of NIAGEN® to improve quality of life. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com"
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://www.en.auh.dk/
http://www.ku.dk/english/

https://academic.oup.com/ajcn/advance-article/doi/10.1093/aj…
"Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health; Findings from Aarhus University Hospital and the University of Copenhagen Suggest Further Studies on NIAGEN® Should Focus on Therapeutic Potential for Liver Health

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen and Aarhus University Hospital, were published yesterday in The American Journal of Clinical Nutrition. The study was led by Jonas T. Treebak, MS, PhD and Niels Jessen, MD, PhD.

The authors conducted a 12-week, randomized, double-blinded, placebo-controlled, parallel-group clinical trial in 40 middle-aged obese men taking a 2 gram dose (1 gram twice daily) of NIAGEN nicotinamide riboside chloride (NR). This is the fourth published clinical study of NR, and the results of this study corroborate previous findings that NR effectively raises levels of nicotinamide adenine dinucleotide (NAD) in humans without adverse effects. This study represents the highest dose, longest-term clinical investigation of NR supplementation to date.

Dr. Charles Brenner, discoverer of NR as a form of vitamin, Chief Scientific Advisor of ChromaDex and co-author of the study commented, “Though previous work established safety of NR in older adults, we needed to look at safety of NR in other populations. In this study, we clearly showed that 2 grams per day of NR is safe in obese men and we were able to assess which metabolic parameters are most sensitive to NR supplementation.” Dr. Brenner serves as the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa.

In addition to confirming the ability of high dose NIAGEN to effectively and tolerably raise NAD levels in obese men, the study assessed a broad range of metabolic factors related to metabolic syndrome and obesity. The authors observed that men taking NR had an average 2% absolute reduction in liver fat content compared to a 0.2% absolute reduction in the placebo group (P=0.13). The authors also looked at the subset of men who started the trial with greater than 5% liver fat. They found a trend that 69% of these men experienced a reduction in liver fat after 12 weeks of NIAGEN compared to only 39% of the men taking the placebo.

The results of this study provide important clues for the role of NIAGEN in supporting liver health and support the need for future clinical studies to determine the effects of NR on liver health in both longer trials and in more diverse populations. “This study supports the safety of high dose NR in obese men and, with further testing, may demonstrate that it provides a beneficial nutritional intervention to reduce liver fat,” said Dr. Brenner.

To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on NIAGEN, the only form of NR with New Dietary Ingredient and Generally Regarded as Safe designations notified to the US Food and Drug Administration. ChromaDex has supplied NIAGEN at no cost to over 140 leading institutions for research including Dartmouth, the National Institutes of Health, University of Iowa, and the Scripps Research Institute.

To learn more about ChromaDex, please visit www.ChromaDex.com.

About NIAGEN®:
NIAGEN®, also known as nicotinamide riboside (NR), is a very unique member of the vitamin B3 family. The body converts NR into Nicotinamide Adenine Dinucleotide (NAD) which is an essential molecule found in every living cell.

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com."
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
http://english.jiangxi.gov.cn/
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol…
"ChromaDex Announces Strategic Partnership for Aging Research with Jiangxi Government in China; New partnership between ChromaDex and First Affiliated Hospital of Nanchang University addresses China’s rapidly aging population

IRVINE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced a strategic partnership for healthy aging research with the Jiangxi Provincial Government, People’s Republic of China.

Wu Zhongqiong, Vice Governor of the People’s Government of Jiangxi Province, commenced the ceremony at the Jiangxi Qianhu State Guesthouse on Thurs., Sept. 13. Additional presentations followed from Madame Wang of Qifeng Food Technology, Dr. Katherine Lo of the Li Ka Shing Foundation, Robert Fried of ChromaDex, and Drs. Charles Brenner and Roger Kornberg of the ChromaDex Scientific Advisory Board.

“We are grateful to have met with the leaders of the great province of Jiangxi and look forward to furthering this relationship,” says ChromaDex CEO Rob Fried. “This is an important first step in our long-term commitment to China.”

“This is a momentous occasion here in Jiangxi,” says Kornberg, who won the Nobel Prize in Chemistry in 2006. “I look forward to the research and progress in the study of aging that will come from this new initiative.”

"I’m thrilled to present the foundational science of nicotinamide riboside (NR) and the safe, evidence-based commercialization of our ingredient to Nanchang and Jiangxi Province,” says Brenner. “The global interest in our technology is exciting, and I look forward to advancing our research and development even further." Brenner discovered NR and is the Chief Scientific Advisor at ChromaDex.

The initiative will allow Jiangxi to become a foothold for advanced scientific research and business development to solve the problem of aging. The parties continue to discuss the details of the relationship, including their respective contributions to the venture, with the anticipation of finalizing definitive agreements later this year.

In addition to the anti-aging initiative, the ceremony also celebrated the launch of the Food Technology Science Park, in collaboration with Qifeng Food Technology Co. of Beijing, to build a world-class, tech-centric science research complex in Jiangxi.

For additional information on the science supporting TRU NIAGEN visit www.truniagen.com.

About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company."